



International Parkinson and
Movement Disorder Society
Asian & Oceanian Section



1999

MOVEMENT DISORDER SOCIETY
OF THE PHILIPPINES, INC.

FINAL PROGRAM

5th Asian and Oceanian Parkinson's Disease and Movement Disorders Congress

March 11–13, 2016 • MANILA, PHILIPPINES



www.aopmc2016.org

Treatment of focal spasticity, including: arm symptoms associated with focal spasticity in conjunction with physiotherapy in adults. Dynamic equinus foot deformity due to spasticity in ambulant paediatric cerebral palsy patients, 2 years of age or older. Spasmodic torticollis, blepharospasm and hemifacial spasm in adults.

CLOSTRIDIUM BOTULINUM TYPE A TOXIN

 **Dysport®**

Be you



 **IPSEN**
Innovation for patient care

Dosage: Adult spasticity of arm post-stroke 1,000 u distributed among the following muscles: Flexor digitorum profundus: 150 u; flexor digitorum superficialis: 150-250 u; flexor carpi ulnaris: 150 u; flexor carpi radialis: 150 u & biceps brachii: 300-400 u. All muscles inj at 1 site except biceps brachii. May be repeated approx 16 weekly but not more frequently than 12 weekly. Cerebral palsy spasticity in children initially 20 u/kg body weight, divided between both calf muscles. If only 1 calf is affected: 10 u/kg body weight. Subsequent dose: May be titrated to 10 & 30 u/kg divided between both legs. Max: 1,000 u. Doses may be given 16 weekly but not more frequently than 12 weekly. Spasmodic torticollis Adult & elderly initially 500 u in divided doses administered to the 2 or 3 most active neck muscles. Rotational torticollis & laterocollis Administer 350 u into the splenius capitis muscle & 150 u into the sternomastoid muscle. Laterocollis associated w/ shoulder elevation Administer 300 u into the splenius capitis, 100 u into the sternomastoid & 100 u into the trapezoid or levator scapulae. Retrocollis Administer 250 u into each of the splenius capitis muscle, may be followed by bilateral trapezius inj (up to 250 u/muscle) after 6 week. Subsequent dose: 250-1,000 u. Bilateral blepharospasm Adult & elderly initially 120 u/eye. Inject 0.1 mL (20 u) medially, 0.2 mL (40 u) laterally into the junction between the preseptal & orbital parts of both the upper & lower orbicularis oculi muscle of each eye. Repeat approx 12 weekly. Dose may need to be reduced to 60-80 u/eye. Unilateral blepharospasm & hemifacial spasm Inj should be confined to the affected eye.

Reference: Dysport® Prescribing information. Available at <http://www.dysport.com>




MENARINI

A. Menarini Philippines, Inc.
4th Floor, W Building, 11th Avenue corner 28th Street,
Bonifacio High Street, Bonifacio Global City
Taguig City 1634, Philippines

PM/2016/03 PHIL-0031-012016

Advance.
Improve.
Educate.
Collaborate.



International Parkinson and
Movement Disorder Society

Become a Member of MDS

Meet & Collaborate
with over 6,000
colleagues across the
globe and become
a part of a Medical
and Educational
community dedicated
to disseminating
knowledge and
promoting research
to advance the field of
Movement Disorders



MDS Members receive the following benefits:

Peer Reviewed Journals: *Movement Disorders* and *Movement Disorders – Clinical Practice*

Quarterly Newsletter: *Moving Along*

Reduced Course Registration Rates

Online Resources: CME Activities; Streaming Content; Training Videos; and a Video Library with over 1,800 searchable videos

NON-MEMBER OPPORTUNITIES

Free One-Year Trial Membership
Open to Eligible AOPMC Delegates

ASSOCIATE MEMBERSHIP

Non-members attending the AOPMC have the opportunity to receive membership with MDS absolutely free for a year. Eligible participants will be invited by e-mail by June to apply for free Associate membership. Interested individuals are encouraged to apply online within 30 days of contact.

Learn more at www.movementdisorders.org/membership.htm or contact the International Secretariat:

MDS International Secretariat
555 E. Wells Street, Suite 1100
Milwaukee, WI 53202 USA
Tel: +1 414-276-2145
Fax: +1 414-276-3349
E-mail: info@movementdisorders.org



Table of Contents

Welcome.....	5
About MDS	6
About MDS-AOS	8
AOPMC Organizing Committee.....	9
AOPMC Meeting Information A-Z.....	10
Venue Floor Plan	12
Award Information	13
AOPMC Schedule-at-a-Glance.....	15
Scientific Program	
Friday, March 11, 2016.....	16
Saturday, March 12, 2016	18
Sunday, March 13, 2016.....	23
Faculty Listing.....	27
Poster Session Schedule	28
Guided Poster Tours	29
Abstract Listing by Topic.....	33
Late-Breaking Abstracts.....	44
Exhibit Area Floor Plans	45
Acknowledgements of Support	47
MDS Education Information	48
Certificate of Attendance.....	51



International Parkinson and
Movement Disorder Society
Asian & Oceanian Section

Dear Colleagues,

On behalf of the International Parkinson and Movement Disorder Society – Asian and Oceanian Section (MDS-AOS) and the Movement Disorder Society of the Philippines (MDSP), we would like to formally welcome you to Manila, Philippines for the 5th Asian and Oceanian Parkinson's Disease and Movement Disorders Congress (AOPMC)!

We would like to express our gratitude to the AOPMC Scientific Program Committee for the hard work and coordination of this diverse program. There are over 70 world renowned experts in the field of Movement Disorders on the Scientific Program showcasing the faculty from the AOS region. We would also like to thank the AOPMC Local Organizing Committee who provided local support to the MDS International Secretariat during the entire planning process.

While in Manila, we hope that you not only allot time in your schedule to participate in our detailed program, visit the exhibit and poster areas and attend the social events, but also get a chance to see the signs and sounds of what makes Manila such a unique destination.

We are pleased to see you in Manila for the 5th AOPMC and thank you for taking the opportunity to be a part of this educational experience.

As we warmly welcome you to the Philippines, we say "*Mabuhay*" to us all!

With kind regards,



Raymond Rosales
Chair,
5th AOPMC
Scientific Program Committee



Roland Dominic Jamora
Chair,
5th AOPMC
Local Organizing Committee



Nobutaka Hattori
Chair,
MDS-AOS
2015-2017

About MDS

The International Parkinson and Movement Disorder Society (MDS) is a professional society of clinicians, scientists, and other healthcare professionals who are interested in Parkinson's disease, related neurodegenerative and neurodevelopmental disorders, hyperkinetic movement disorders, and abnormalities in muscle tone and motor control. The spectrum of clinical disorders represented by the Society includes, but is not limited to:

- Ataxia
- Chorea
- Dystonia
- Gait disorders
- Huntington's disease
- Myoclonus and startle
- Parkinson's disease and parkinsonism
- Restless legs syndrome
- Spasticity
- Stiff person syndrome
- Tardive dyskinesia
- Tics and Tourette syndrome
- Tremor and essential tremor

In recent years, there has been tremendous growth in new diagnostic information, pharmacological and neurosurgical treatments for Movement Disorders, as well as a greater understanding of impaired motor control function. MDS offers you and your patients an essential link to this knowledge.

In 1985, The *Movement* Disorder Society was founded on the initiative of Professors Stanley Fahn and C. David Marsden, whose leadership and vision guided the expansion of clinical expertise and research in this field. This not-for-profit organization merged in 1992 with the International Medical Society for Motor Disturbances. Publication of the journal *Movement* Disorders began in 1986, and the first International Congress was held in 1990.

In 2013, The *Movement* Disorder Society officially changed its name to the International Parkinson and Movement Disorder Society, in order to recognize the growing importance of Parkinson's disease care and research within the field of Movement Disorders.

Purpose, Mission And Goals

Purpose:

The objective and mission of the Society shall be to advance the neurological sciences pertaining to Movement Disorders; to improve the diagnosis and treatment of patients; to operate exclusively for scientific, scholarly and educational purposes; to encourage research; to provide forums, such as medical journals, scientific symposia and International Congresses, for sharing ideas and for advancing the related clinical and scientific disciplines; to encourage interest and participation in the activities of the Society among healthcare and allied professionals and scientists; and to collaborate with other related professional and lay organizations.

Mission and Goals:

To disseminate knowledge about movement disorders by:

- Providing educational programs for clinicians, scientists and the general public designed to advance scientific and clinical knowledge about movement disorders
- Sponsoring International Congresses and Symposia on movement disorders
- Collaborating with other international organizations and lay groups
- Publishing journals, videotapes and other collateral materials committed to high scientific standards and peer review

To promote research into causes, prevention and treatment of movement disorders by:

- Using the Society's influence and resources to enhance support for research
- Facilitating the dissemination of information about research
- Encouraging the training of basic and clinical scientists in movement disorders and related disorders

For the purposes of favorably affecting the care of patients with movement disorders, the Society will provide expertise, advice and guidance to:


- Regulatory agencies to assist them in the approval process of safe and effective therapeutic interventions
- The public (media) and patient support groups by informing them of new research and therapeutic advances
- Governments to assist them in the development of policies that affect support of research and patient care
- Educational efforts to assist in developing standards of training in the specialty




International Parkinson and
Movement Disorder Society
Asian & Oceanian Section

About MDS

MDS OFFICERS (2015-2017)



President
Oscar Gershanik,
Argentina



President-Elect
Christopher Goetz,
USA




Secretary
Claudia Trenkwalder,
Germany



Secretary-Elect
Susan Fox,
Canada



Treasurer
David John Burn,
United Kingdom



Treasurer-Elect
Victor Fung,
Australia



Past-President
Matthew Stern,
USA

MDS International Executive Committee

Paolo Barone, *Italy*
Daniela Berg, *Germany*
Bastiaan Bloem, *Netherlands*
Carlos Cosentino, *Peru*
Beom Jeon, *Korea*
Jeffrey Kordower, *USA*
Michael Okun, *USA*
Mark Stacy, *USA*
Ryosuke Takahashi, *Japan*
Louis Tan, *Singapore*

Past-Presidents

2013-2015 Matthew Stern, *USA*
2011-2013 Günther Deuschl, *Germany*
2009-2011 Philip Thompson, *Australia*
2007-2009 Anthony Lang, *Canada*
2005-2006 Andrew Lees, *United Kingdom*
2003-2004 C. Warren Olanow, *USA*
2001-2002 Werner Poewe, *Austria*
1999-2000 Mark Hallett, *USA*
1997-1998 Eduardo Tolosa, *Spain*
1995-1996 Joseph Jankovic, *USA*
1991-1994 C. David Marsden, *United Kingdom*
1988-1991 Stanley Fahn, *USA*

International Medical Society for Motor Disturbances Past-Presidents

1993-1994 C. Warren Olanow, *USA*
1991-1992 Bastian Conrad, *Germany*
1989-1990 Mark Hallett, *USA*
1987-1988 Mario Manfredi, *Italy*
1985-1986 C. David Marsden, *United Kingdom*

MDS International Secretariat

International Parkinson and Movement Disorder Society
555 East Wells Street, Suite 1100
Milwaukee, WI 53202-3823 USA
Tel: +1 414-276-2145
Fax: +1 414-276-3349
info@movementdisorders.org
www.movementdisorders.org

About MDS-AOS

MDS-AOS Officers



Chair
Nobutaka Hattori,
Japan



Chair-Elect
Beom Jeon,
Korea



Secretary
Raymond Rosales,
Philippines



Secretary-Elect
Shen-Yang Lim,
Malaysia



Treasurer
Carolyn Sue,
Australia



Treasurer-Elect
Yasuyuki Okuma,
Japan



Past-President
Louis Tan,
Singapore

MDS Asian and Oceanian Section

The mission of MDS-AOS is to represent and promote the International Parkinson and Movement Disorder Society (MDS) in Asia and Oceania. Membership of MDS-AOS is open to all members of MDS within the Asian and Oceanian region.

The Asian and Oceanian Section was formed in 2006 at the 10th International Congress of Parkinson's Disease and Movement Disorders in Kyoto, Japan. The MDS-AOS aims to facilitate communication between clinicians and researchers in the region; disseminate updated knowledge about Movement Disorders; improve quality of life and independence of movement disorders patients and caregivers; and promote research in Movement Disorders within the region.

For further information on MDS-AOS or its educational opportunities, please visit
www.movementdisorders.org/MDS-AOS.

MDS-AOS Executive Committee

Mandy Au-Yeung, *Hong Kong*
Jou-Hsien Chen, *Taiwan*
Vinay Goyal, *India*
Roland Dominic Jamora, *Philippines*
Hee Tae Kim, *Korea*
Thomas Kimber, *Australia*
Miho Murata, *Japan*
Hui Fang Shang, *People's Republic of China*
Yih-Ru Wu, *Taiwan*
Baorong Zhang, *People's Republic of China*

MDS-AOS Education Committee

Co-Chair: Shen-Yang Lim, *Malaysia*
Chair: Hui Fang Shang, *People's Republic of China*
Jawad Bajwa, *Saudi Arabia*
Jae Woo Kim, *Korea*
Simon Lewis, *Australia*
Hideki Mochizuki, *Japan*
Pramod Pal, *India*
Thamrin Syamsudin, *Indonesia*
Win Min Thit, *Myanmar*
Qin Xiao, *People's Republic of China*



AOPMC Organizing Committees

Oversight Committee

Chair: Nobutaka Hattori, *Japan*
Roongroj Bhidayasiri, *Thailand*
Cid Diesta, *Philippines*
Roland Dominic Jamora, *Philippines*
Raymond Rosales, *Philippines*
Carolyn Sue, *Australia*
Louis Tan, *Singapore*
Ruey-Meei Wu, *Taiwan*

Scientific Program Committee

Chair: Raymond Rosales, *Philippines*
Mandy Au-Yeung, *Hong Kong*
Jawad Bajwa, *Saudi Arabia*
Cid Diesta, *Philippines*
Hubert Fernandez, *USA/Philippines*
Roland Dominic Jamora, *Philippines*
Shen-Yang Lim, *Malaysia*
Carolyn Sue, *Australia*
Yoshikazu Ugawa, *Japan*
Yih-Ru Wu, *Taiwan*

Local Organizing Committee

Chair: Roland Dominic Jamora
Co-Chair: Cid Diesta
Lucy Kathrina Banta-Banzali
Donna Buhat
Criscely Go
Arlene Ng
Jean-Quint Oropilla
Rafael Palacio
Anthony Piano
Rosalia Teleg

Honorary Advisor

Lillian Lee, *Philippines*

Video Tournament Committee

Donna Buhat, *Philippines*
Han-Lin Chiang, *Taiwan*
Thien Thien Lim, *Malaysia*
Zheyu Xu, *Singapore*



5th AOPMC Meeting Information A-Z

Abstracts

All accepted abstracts (including Late-Breaking) are presented as a poster at the 5th AOPMC. Authors are to be present at their poster from 11:30-12:30 on Saturday, March 12 and Sunday, March 13. All regular accepted abstracts are published as an online supplement to the *Movement Disorders Journal*. Additionally, select abstracts are presented in a Guided Poster Tour. Please visit www.aopmc2016.org for further publication information.

All registered AOPMC delegates will also receive the published abstracts on a USB, available for pickup in the registration area during regular Congress hours.

For further information regarding abstracts and poster presentation schedules, please see page 28.

Late-Breaking Abstracts

All accepted Late-Breaking Abstract posters are displayed in the Marriott Grand Ballroom, Ground Floor Foyer on Saturday and Sunday. These poster presentations will take place on Saturday, March 12 from 11:30 – 12:30. The Late-Breaking Abstracts will be available on the AOPMC website (www.aopmc2016.org) as of Friday, March 11.

For further information regarding Late-Breaking, abstracts and poster presentation schedules, please see page 44.

Badges

All AOPMC attendees will receive a name badge with their registration materials. Badges should be worn at all times as they are used to gain access into all AOPMC sessions and activities.

Certificate of Attendance

A certificate of attendance is available in the back of the AOPMC Final Program or at the registration desk.

Coffee Breaks

Coffee and tea will be available in Executive Room 7 and 9 and Ceremonial Hall, Ground Floor at the following times:

Friday, March 11	15:30 – 16:00
Saturday, March 12	9:30 – 10:00

**The Saturday morning coffee break is sponsored by H. Lundbeck A/S*

Saturday, March 12	16:00 – 16:30
Sunday, March 13	9:30 – 10:00

Currency

The official currency of the 5th AOPMC is US Dollars and Philippine Pesos; no other currency will be accepted.

Evaluations

Please take time to complete the evaluation form provided at each session you attend. Your input and comments are essential in planning future educational programs for MDS.

Upon completion, evaluations may be returned to the session room attendants, or to the registration desk (located in the Box Office, Ground Floor).

Events

Opening Ceremony

Friday, March 11

Location: Ballroom CD, Second Floor

18:30 to 19:30

All AOPMC attendees are warmly invited to attend the Welcome Ceremony at the Marriott Grand Ballroom with a reception to follow. This event is open to all registered delegates.

The MDS-AOS would like to acknowledge Boehringer Ingelheim for their support of the Opening Ceremony through an unrestricted grant.

AOPMC Video Tournament

Saturday, March 12

Location: Ballroom CD, Second Floor

18:30 – 20:30

Please join Masters of Ceremony Victor Fung and Janis Miyasaki as they host this interactive tournament which will challenge participants to improve diagnostic skills with unique and interesting cases. This event is open to all registered delegates.

Exhibition

Location: Executive Rooms 7 and 9 and Ceremonial Hall, Ground Floor

For more information, please refer to page 45.

Friday, March 11:	13:00 – 20:00
Saturday, March 12:	9:00 – 18:30
Sunday, March 13:	9:00 – 16:30

Floor Plans of the Marriott Grand Ballroom

Please refer to page 12.



International Parkinson and
Movement Disorder Society
Asian & Oceanian Section

5th AOPMC Meeting Information A-Z

Guided Poster Tours

Guided Poster Tours will give small groups of delegates an opportunity to hear discussion by abstract authors on a select group of abstracts in several sub-categories led by members of the AOPMC faculty. There will be ten total Guided Poster Tours with five simultaneous tours per day during the regular poster sessions on Saturday, March 12 and Sunday, March 13. Anyone is welcome to attend; please meet at the first poster of the tour at the start time. Each tour will highlight exceptional posters.

Please refer to page 29 for further Guided Poster Tour information and schedules.

The MDS-AOS would like to acknowledge Aguetant for their support of the Guided Poster Tours through an unrestricted grant.

Internet

Complimentary Wi-Fi will be available throughout the Marriott Grand Ballroom for all attendees.

Username: AOPMC2016

Password: AOPMC2016

Official Language

The official language of the AOPMC is English.

Registration Desk

Location: Box Office, Ground Floor

Name badges, abstract USBs, Final Programs and AOPMC meeting bags can be collected at the AOPMC Registration Area.

Registration Desk hours are as follows:

Friday, March 11: 8:00 – 18:00

Saturday, March 12: 7:00 – 18:00

Sunday, March 13: 7:00 – 16:00

Special Accessibility Needs

MDS will make every effort to work with the Marriott to accommodate these requests. Delegates requiring special arrangements in order to fully participate in the meeting should provide a written description of such needs to the registration desk upon arrival.

Speaker Ready Room

Location: Executive Room 15, Second Floor

All speakers must check in at the Speaker Ready Room with their presentation materials at least two hours prior to their scheduled presentation. Equipment is available to allow faculty and presenters to review their presentations. Audio/Visual personnel will be available for assistance.

The Speaker Ready Room hours are as follows:

Friday, March 11: 8:00 – 19:00

Saturday, March 12: 7:00 – 18:00

Sunday, March 13: 7:00 – 16:00




We believe in the
Power of Nutrition.
We call it the **N**FACTOR

Marriott Grand Ballroom Floor Plan


Ground Floor



Second Floor



Third Floor






MDS-AOS Lectureship Awards

The MDS-AOS lectureships were established to honor Professors Yoshikuni Mizuno and Philip Thompson as experts in the field of Movement Disorders and to recognize their contributions as leaders within the International Parkinson and Movement Disorder Society. The lectureships also honor their leadership role in establishing the MDS Asian and Oceanian Section (MDS-AOS) in 2006 at the 10th International Congress of Parkinson's Disease and Movement Disorders in Kyoto, Japan. The award lectures will be presented during the MDS-AOS Lectureship Plenary session on Sunday, March 13, 2016.

Session 3101: MDS-AOS Lectureship Awards

Sunday, March 13
8:00 – 9:30



2016 Philip Thompson Lectureship Award Recipient:

Lillian Lee, MD

*4 Decades with XDP (Sex Linked Dystonia
Parkinsonism)*

The Philip Thompson Award Lecture is created to recognize an outstanding scholar and role-model clinician from the AOS region in the field of Movement Disorders. This year's recipient is Dr. Lillian Lee.

Dr. Lillian V. Lee is head of the Philippine XDP Study Group based at the Philippine Children's Medical Center in Quezon City, Philippines. The XDP Study Group tracks the clinical course of the disease called X-Linked Dystonia Parkinsonism (XDP, DYT3, Lubag), an adult onset, progressive, often debilitating movement disorder, manifesting predominantly with dystonia in combination with parkinsonism first reported in 1976 in 28 cases, occurring endemically among males in Panay Islands, Philippines. The group started surveillance of XDP cases since then.

Dr. Lee is also head of research and active consultant at the Child Neuroscience Center of the Philippine Children's Medical Center. In July 2014, she received the appointment as Research Scientist in Neurology from Massachusetts General Hospital. She is a former Executive Director of the Philippine Children's Medical Center, founding member of the Philippine Neurological Association, founding president and fellow of the Child Neurology Society of the Philippines and adviser to the Movement Disorder Society of the Philippines.

2016 Yoshikuni Mizuno Lecture Award Recipient:



Eng-King Tan, MD

*Linking Lrrk2 with Parkinson's Disease: From
Bench to Bedside*

The Yoshikuni Mizuno Award Lecture was created to recognize an outstanding scholar and inspiring neuroscientist from the AOS region in the field of Movement Disorders. This year's recipient is Dr. Eng-King Tan.

Dr. Eng-King Tan is a senior consultant neurologist and clinician scientist at the National Neuroscience Institute (NNI) and a Professor at Duke-NUS graduate medical school. Dr. Tan completed his neurology training in Singapore and received further clinical fellowship training in Movement Disorders under the Ministry of Health Scholarship, and subsequently a research fellowship in Neurogenetics. He completed both fellowships at the Baylor College of Medicine, in Texas, USA.

Dr. Tan is an editor of the *European Journal of Neurology*, *Parkinsonism Related Disorders*, *Parkinson's disease Journal*, and *Basal Ganglia journal*, and the chief editor of *Annals Academy of Medicine*, Singapore. Dr. Tan has served on various committees in the International Parkinson and Movement Disorder Society (MDS) and a founding member of the MDS Asian and Oceanian Section. He is also member of American Neurological Association. He has been involved in numerous educational activities in the Asian and Oceanian region.

Dr. Tan's primary research interests are in clinical and functional genomics and experimental therapeutics in Parkinson's disease and movement disorders.

Junior Award

Junior Award recipients are selected based on their significant contribution to the research in the field of Movement Disorders.

Hiroyuki Todo, MD

Japan

Attenuation of antecollis increases the blood concentration level of the levodopa in patients with the Parkinson's disease and related disorders

Hiroyuki Todo, Yuji Saitoh, Shoko Watanabe, Yohei Mukai, Takashi Sakamoto, Miho Murata (Kodaira, Japan)

Objective: To investigate whether antecollis affects the pharmacokinetics of levodopa in patients with Parkinson's disease (PD) and related disorders.

Background: Antecollis is one of the abnormal postures complicated with PD and related disorders. Antecollis can affect the levodopa pharmacokinetics by disturbing the drug delivery especially in the pharynx, delaying its absorption.

Methods: The subjects were 9 patients, including 4 PD patients, 3 multiple system atrophy (MSA) patients, 1 dementia with Lewy bodies (DLB) patient, and 1 progressive supranuclear palsy (PSP) patient, concomitant with antecollis. To investigate whether antecollis affects the pharmacokinetics of levodopa or the motor symptoms, we examined them before and until 240 minutes after oral administration of levodopa/decarboxylase inhibitor (L-dopa test). Then we did L-dopa test again after the treatment of antecollis by the physical therapy to show the effects of the improvement of antecollis.

Results: Before the treatment of antecollis, in 6 out of 9 patients (PD=2, MSA=2, DLB=1, PSP=1), levodopa kinetics showed two peaks. After the treatment of antecollis, the levodopa kinetics showed monophasic pattern in 5 patients, furthermore, the C_{max} became higher than that before the treatment of antecollis in all of 9 patients. Interestingly, in a PD patient, the higher C_{max} ameliorated the motor symptoms after the treatment of antecollis.

Conclusions: Our study indicates that antecollis affects the pharmacokinetics of levodopa. The treatment of antecollis could ameliorate the motor symptoms by getting the higher concentration of levodopa, especially in PD patients. Further studies are needed to elucidate the mechanisms of these pharmacokinetic changes of levodopa attributed to antecollis.





Schedule-at-a-Glance

	Friday, March 11	Saturday, March 12		Sunday, March 13		
8:00		Plenary Session I 8:00 - 9:30		Plenary Session III: MDS-AOS Lectureship Awards 8:00 - 9:30	The 11th International Symposium of the Asian and Pacific Parkinsonism Association (APPA), a meeting for People Living with Parkinson's and their caregivers 9:00 - 16:00	
8:30						
9:00						
9:30		Tea/Coffee Break 9:30 - 10:00		Tea/Coffee Break 9:30 - 10:00		
10:00		Plenary Session II 10:00 - 11:30		Plenary Session IV 10:00 - 11:30		
10:30						
11:00		Poster Session/Late-Breaking Poster Session/ Guided Poster Tours 11:30 - 12:30		Poster Session/ Guided Poster Tours 11:30 - 12:30		
11:30						
12:00		Ipsen Lunch Symposium 12:00 - 13:00	Break 12:30 - 13:00			Break 12:30 - 13:00
12:30						
13:00	Break 13:00 - 13:15	Lundbeck Lunch Symposium 13:00 - 14:00		Lunch Symposium 13:00 - 14:00		
13:30	Novartis Symposium 13:15 - 14:15					
14:00	Break 14:15 - 14:30	Break 14:00 - 14:30	APPA: Regional PD Societies Leadership Forum (only for leaders of regional PD patient/ caregiver Societies) 14:00 - 18:00	Break 14:00 - 14:30		
14:30						
15:00	AOPMC Symposium 14:30 - 15:30	Parallel Sessions (3) 14:30 - 16:00		Parallel Sessions (3) 14:30 - 16:00		
15:30	Tea/Coffee Break 15:30 - 16:00	Tea/Coffee Break 16:00 - 16:30		Break 16:00 - 16:30		
16:00	AbbVie Symposium 16:00 - 17:00					
16:30	Break 17:00 - 17:15	Parallel Sessions (3) 16:30 - 18:00		Parallel Sessions (3) 16:30 - 18:00		
17:00						
17:30	UCB Symposium 17:15 - 18:15					
18:00	Break 18:15 - 18:30	Break 18:00 - 18:30				
18:30						
19:00	Opening Ceremony 18:30 - 19:30	Video Tournament 18:30 - 20:30				
19:30	Opening Reception 19:30 - 20:00					
20:00	Medtronic Dinner Symposium 20:00 - 21:00					

The 11th International
Symposium of the Asian
and Pacific Parkinsonism
Association (APPA),
a meeting for People
Living with Parkinson's
and their caregivers
9:00 - 16:00

Registration Desk Hours

Friday, March 11: 8:00 - 18:00
Saturday, March 12: 7:00 - 18:00
Sunday, March 13: 7:00 - 16:00

Exhibition Hours

Friday, March 11: 13:00 - 20:00
Saturday, March 12: 9:00 - 18:30
Sunday, March 13: 9:00 - 16:30

5th AOPMC Scientific Program

Friday, March 11, 2016

<p>1101 Ipsen Lunch Symposium</p> <p>Role of Botulinum Toxin in the Management of Spasticity (Sponsored by Ipsen) 12:00 – 13:00</p> <p>Location: Ballroom AB, Second Floor</p> <p>New Data for Abobotulinumtoxin A in the Treatment of Adults with Upper Limb Spasticity Jean-Michel Gracies France</p> <p>Results from an International Survey of Patients with Spasticity Raymond Rosales Philippines</p>	<p>1103 AOPMC Symposium</p> <p>Movement Disorders in Autoimmune Disease and Paraneoplastic Disorders 14:30–15:30</p> <p>Location: Ballroom CD, Second Floor</p> <p>Chairs: Donna Buhat Philippines Vinay Goyal India</p> <p>Movement Disorders Associated with Autoimmune Diseases Simon Lewis Australia</p> <p>Paraneoplastic Movement Disorders Vinay Goyal India</p>
<p>1102 Novartis Symposium</p> <p>Challenges, Trends and Future Perspectives in Parkinson's Disease and Dementia: A Novartis Symposium (Sponsored by Novartis) 13:15–14:15</p> <p>Location: Ballroom CD, Second Floor</p> <p>Chair: Nobutaka Hattori Japan</p> <p>Effective Management of Motor Fluctuations in Advanced Parkinson's Disease – Current and Future Perspectives Eng-King Tan Singapore</p> <p>Parkinson's Disease Dementia: Where Memory Fails and Management Re-Challenged Raymond Rosales Philippines</p>	<p>At the conclusion of this session, participants should be better able to:</p> <ol style="list-style-type: none"> 1. Identify the phenomena of movement disorders in autoimmune disease and paraneoplastic disorders 2. Recognize the underlying pathogenesis 3. Describe how to manage patients with these diseases



International Parkinson and
Movement Disorder Society
Asian & Oceanian Section

5th AOPMC Scientific Program

Friday, March 11, 2016, *continued*

1104	AbbVie Symposium Advanced Parkinson's Disease – Natural Progression, Emerging Data and Patient Profile Considerations in the Clinical Setting <i>(Sponsored by AbbVie)</i> 16:00-17:00 Location: Ballroom CD, Second Floor Chair: Carolyn Sue <i>Australia</i> Advanced Parkinson's Disease Landscape – Incidence, Definition and Patient Considerations Including Emerging Data for Advanced Parkinson's Disease Treatment Options Thomas Kimber <i>Australia</i> Which Patient for Which Therapy and When? Is There a Clear Patient Profile for the Different Advanced Parkinson's Disease Therapies? Andrew Evans <i>Australia</i>
1105	UCB Symposium How Can We Empower Our Parkinson's Disease Patients and Optimize Clinical Outcomes? <i>(Sponsored by UCB)</i> 17:15 – 18:15 Location: Ballroom CD, Second Floor Chair: Andrew Evans <i>Australia</i> Patients & Neurologists – A Partnership for Success Andrew Evans <i>Australia</i> Integrating Patient Concerns into Disease Management Shen-Yang Lim <i>Malaysia</i> Joint Decisions on Treating Nocturnal Symptoms – What Do Patients Need to Know? Roongroj Bhidayasiri <i>Thailand</i>

Opening Ceremony
(Sponsored by Boehringer Ingelheim)
18:30 – 19:30
Location: Ballroom CD, Second Floor

Opening Reception
19:30 – 20:00
Location: Ballroom Foyer, Second Floor

1106	Medtronic Dinner Symposium Incorporating Medtronic DBS in Your Practice <i>(Sponsored by Medtronic)</i> 20:00 – 21:00 Location: Ballroom AB, Second Floor Chair: Roland Dominic Jamora <i>Philippines</i> When is the Right Time for DBS? Shen-Yang Lim <i>Malaysia</i> Optimizing DBS Outcomes – A Review of Recent Evidence Vincent Mok <i>People's Republic of China</i>
-------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

5th AOPMC Scientific Program

Saturday, March 12, 2016

2101	Plenary Session I	2102	Plenary Session II
	Basal Ganglia Circuitry and Receptors: New Developments in Understanding Movement Disorders 8:00 – 9:30		Phenotype/Genotype in Movement Disorders 10:00 – 11:30
Location:	Ballroom CD, Second Floor	Location:	Ballroom CD, Second Floor
Chairs:	Saeed Bohlega <i>Saudi Arabia</i> Jou-Hsien Chen <i>Taiwan</i>	Chairs:	Nobutaka Hattori <i>Japan</i> Eng-King Tan <i>Singapore</i>
8:00	Opening Keynote Address: Psychogenic Movement Disorders Oscar Gershanik <i>Argentina</i>	10:00	The Very Latest on the Genetics of Dystonia Christine Klein <i>Germany</i>
8:30	The Basal Ganglia Circuitry: Overview and New Developments Philip Thompson <i>Australia</i>	10:30	Keeping Up with New Genetic Predispositions and Mutations in Parkinson's Disease Manabu Funayama <i>Japan</i>
8:50	The Default Mode Networks in The Basal Ganglia Through Neuroimaging Shunsuke Kobayashi <i>Japan</i>	11:00	Unique Genetic Considerations in Movement Disorders in the Asian Population Ruey-Meei Wu <i>Taiwan</i>
9:10	Moving New Developments of Basal Ganglia Circuitry into Clinical Translation Jawad Bajwa <i>Saudi Arabia</i>	Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Students/Residents/Trainees	
Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Students/Residents/Trainees		At the conclusion of this session, participants should be better able to:	
At the conclusion of this session, participants should be better able to:		1. Update the very latest on dystonia genomics	
1. Develop a clinical working framework in approaching psychogenic movement disorders		2. Describe the genetic etiologies and underlying mechanisms causing parkinsonism	
2. Integrate new developments in the understanding of the basal ganglia circuitry, as it relates to movement disorders		3. Assess the ethnic difference of genetic etiology in Parkinson's disease and other movement disorders in the Asian population	
3. Recognize the relevance our current knowledge of the basal ganglia has to the clinical presentation of movement disorders			
4. Describe the emerging role of different neural networks in translating a better understanding and treatment of movement disorders			



5th AOPMC Scientific Program

Saturday, March 12, 2016, *continued*

2203	Lundbeck Lunch Symposium	2304	Parallel Session
	Asian Perspectives on Recognition and Treatment of Levodopa - Induced Motor Complications in Parkinson's Disease (Sponsored by H. Lundbeck A/S) 13:00 – 14:00		How to Engage in Clinical Trials for Movement Disorders 14:30 – 16:00
Location:	Ballroom AB, Second Floor	Location:	VIP West, Third Floor
Chair:	Roland Dominic Jamora <i>Philippines</i>	Chairs:	Hubert Fernandez <i>USA/Philippines</i> Masahiro Nomoto <i>Japan</i>
	Focus on Parkinson's Disease in the Philippines Roland Dominic Jamora <i>Philippines</i>	14:30	Introduction to Clinical Trials: The Basics and the Winning Formula Hubert Fernandez <i>USA/Philippines</i>
	Clinical Management of Parkinson's Disease in Asia – Recent Developments in use of Levodopa Piu Bill Chan <i>People's Republic of China</i>	14:55	What You Need To Know Before Conducting Clinical Trials - Ethics, Regulatory Concerns, and Investigator Responsibilities Janis Miyasaki <i>Canada</i>
	Levodopa - Related Motor Complications in Parkinson's Disease -Mechanisms and Treatment Approaches Werner Poewe <i>Austria</i>	15:20	Avoiding/Surviving the Dreaded 'Audit': How Regulators Spot Trouble Anne Constantino <i>USA</i>
		15:45	Maximize Recruitment and Retention While Minimizing Placebo Effect: An Interactive Session with the Audience The Panel
			Recommended Audience: Clinical academicians, Health Professionals (Non-physician), Practitioners, Students/Residents/Trainees
			At the conclusion of this session, participants should be better able to:
			1. Provide an overview of the different phases of clinical trials and the required set up in conducting clinical trial
			2. Recognize the ethical, clinical and regulatory responsibilities of a clinical trial investigator
			3. Recognize various techniques to maximize recruitment and retention and minimize placebo effect in clinical trials

5th AOPMC Scientific Program

Saturday, March 12, 2016, *continued*

2305	Parallel Session
	Management of Common and Intractable Cervical Dystonia 14:30 – 16:00
Location:	Executive Room 11 and 12, Second Floor
Chairs:	Ying-Zu Huang <i>Taiwan</i> Hee-Tae Kim <i>Korea</i>
14:30	Common and Uncommon Clinical Presentations and Etiologies of Cervical Dystonia Erle Lim <i>Singapore</i>
15:00	Non-Surgical Managements for Cervical Dystonia Barry Snow <i>New Zealand</i>
15:30	Surgical Interventions to Consider for Cervical Dystonia: When And What Takaomi Taira <i>Japan</i>
Recommended Audience: Clinical academicians, Practitioners, Students/Residents/Trainees	
At the conclusion of this session, participants should be better able to:	
<ol style="list-style-type: none"> 1. Recognize the clinical presentations and etiologies of cervical dystonia and review the treatment options of intractable cervical dystonia 2. Assess the current evidence base of applying novel intervention (tDCS and cerebellar stimulation) for intractable cervical dystonia 3. Recognize the role of surgical interventions for the treatment of cervical dystonia 	

2306	Parallel Session
	Hyperkinetic Movement Disorders: The Common, The Rare, and The Traps 14:30 – 16:00
Location:	Ballroom CD, Second Floor
Chairs:	Madhuri Behari <i>India</i> Frandy Susatia <i>Indonesia</i>
14:30	What You Cannot Afford to Miss: Common Hyperkinetic Movement Disorders Werner Poewe <i>Austria</i>
15:00	How To Be The Hero: Recognizing Uncommon Hyperkinetic Movement Disorders Thien Thien Lim <i>Malaysia</i>
15:30	Is It Real Or Not? Spotting Mimickers of Hyperkinetic Movement Disorders Mohit Bhatt <i>India</i>
Recommended Audience: Clinical academicians, Practitioners, Students/Residents/Trainees	
At the conclusion of this session, participants should be better able to:	
<ol style="list-style-type: none"> 1. Recognize the phenotypic spectrum of common hyperkinetic movement disorders 2. Describe the phenotypic spectrum of uncommon hyperkinetic movement disorders 3. Recognize mimics of hyperkinetic movement disorders 	



5th AOPMC Scientific Program

Saturday, March 12, 2016, *continued*

2407	Parallel Session	2408	Parallel Session
	Spasticity, Plasticity and Botulinum Toxin Therapy - The Word Gets Around 16:30 – 18:00		Appreciating Hyperkinetic Movements Based on Their Patho-Mechanism 16:30 – 18:00
Location:	Executive Room 11 and 12, Second Floor	Location:	VIP West, Third Floor
Chairs:	Cid Diesta <i>Philippines</i> Yasuyuki Okuma <i>Japan</i>	Chairs:	Yoshikuni Mizuno <i>Japan</i> Miho Murata <i>Japan</i>
16:30	The Pathophysiology of Spasticity: Integrating the Old and New Concepts Jean-Michel Gracies <i>France</i>	16:30	How Can Understanding the Pathomechanism of Tremors and Ataxia Alter Our Diagnosis and Treatment? Victor Fung <i>Australia</i>
17:00	Brain Plasticity in Spasticity with Toxin Therapy? Evidence from Imaging Studies Petr Kanovsky <i>Czech Republic</i>	17:00	Overview of the Patho-Mechanisms Underlying Voluntary and Involuntary Movements Yoshikazu Ugawa <i>Japan</i>
17:30	Optimizing Spasticity Management with Botulinum Toxin A Therapy Raymond Rosales <i>Philippines</i>	17:30	Recognizing Dystonic Types and Optimizing Treatment Through the Mechanistic Lens Ryuji Kaji <i>Japan</i>
Recommended Audience: Clinical academicians, Practitioners, Students/Residents/Trainees		Recommended Audience: Clinical academicians, Practitioners, Students/Residents/Trainees	
At the conclusion of this session, participants should be better able to:		At the conclusion of this session, participants should be better able to:	
<ol style="list-style-type: none">1. Integrate old and new concepts in understanding the pathophysiology of spasticity2. Summarize the therapeutic roles of Botulinum toxin A injections in spasticity management3. Define brain plasticity in spasticity in the context of Botulinum toxin A therapy, focusing on the evidence from MRI studies		<ol style="list-style-type: none">1. Describe mechanisms underlying four groups of hyperkinetic involuntary movements: Myoclonus, tremor, chorea-ballism, dystonia-athetosis groups2. Differentiate tremors and ataxia and their treatment options based on their mechanism3. Recognize dystonic forms and select optimal treatments using drugs, botulinum toxin and DBS through the pathomechanistic standpoint	

5th AOPMC Scientific Program

Saturday, March 12, 2016, *continued*

2409	Parallel Session
	Hot Topics in Parkinson's Disease Non-Motor Symptoms
	16:30 – 18:00
Location:	Ballroom CD, Second Floor
Chairs:	Norlinah Ibrahim <i>Malaysia</i> Anthony Piano <i>Philippines</i>
16:30	Gastrointestinal Dysfunction in Parkinson's Disease: Etio-Pathogenetic Aspects
	Shen-Yang Lim <i>Malaysia</i>
17:00	The Painful Truth About Pain in Parkinson's Disease
	Beom Jeon <i>Korea</i>
17:30	Autonomic Manifestations in Parkinson's Disease
	Ryuji Sakakibara <i>Japan</i>

Recommended Audience: Clinical academicians, Health Professionals (Non-physician), Practitioners, Students/Residents/Trainees


At the conclusion of this session, participants should be better able to:

1. Explain the role of the gut in the pathogenesis of Parkinson's disease (disease causation, and/or worsening of disease severity)
2. Elucidate the occurrence of pain and its pathogenesis in Parkinson's disease
3. Describe the role of the autonomic nervous system in the pathogenesis of Parkinson's disease (disease causation, and/or worsening of disease severity)

MDS-AOS Video Tournament

18:30 – 20:30

Location: Ballroom CD, Second Floor





5th AOPMC Scientific Program

Sunday, March 13, 2016

3101	Plenary Session III
	MDS-AOS Lectureship Awards 8:30 – 9:30
Location:	Ballroom AB, Second Floor
Chairs:	Nobutaka Hattori <i>Japan</i> Raymond Rosales <i>Philippines</i>
8:00	Philip Thompson Lecture: Four Decades with XDP (Sex Linked Dystonia Parkinsonism) Lillian Lee <i>Philippines</i>
8:30	Yoshikuni Mizuno Lecture: Linking Lrrk2 with Parkinson's Disease: From Bench to Bedside Eng-King Tan <i>Singapore</i>
9:00	Junior Award Lectureships Hiroyuki Todo <i>Japan</i>

3102	Plenary Session IV
	Care in Parkinson's Disease 10:00 – 11:30
Location:	Ballroom AB, Second Floor
Chairs:	Vinay Goyal <i>India</i> Mitsutoshi Yamamoto <i>Japan</i>
10:00	Gaps in the Diagnosis and Care of Parkinson's Disease: Focus on Asia Roland Dominic Jamora <i>Philippines</i>
10:30	The Critical Role of Neurorehabilitation in Parkinson's Disease Care Jorge Hernandez Franco <i>Mexico</i>
11:00	Why Palliative Care in Parkinson's Disease Should Be Everyone's Responsibility Janis Miyasaki <i>Canada</i>

Recommended Audience: Clinical academicians, Health Professionals (Non-physician), Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Identify key problem areas in the diagnosis and care of Parkinson's disease in Asia
2. Define the role of neurorehabilitation in the management of Parkinson's disease
3. Integrate the principles of palliative care and its applicability in Parkinson's disease management

3103	Lunch Symposium
	13:00 – 14:00
Location:	Ballroom AB, Second Floor

5th AOPMC Scientific Program

Sunday, March 13, 2016, *continued*

3304	Parallel Session	3305	Parallel Session
	Neurobehavioral Impairment in Parkinson's Disease 14:30 – 16:00		Manifesting Movement Disorders in Neuromuscular Disease 14:30 – 16:00
Location:	Ballroom AB, Second Floor	Location:	Executive Room 11 and 12, Second Floor
Chairs:	Jae Woo Kim <i>Korea</i> Hui Fang Shang <i>People's Republic of China</i>	Chairs:	Ritsuko Hanajima <i>Japan</i> Arlene Ng <i>Philippines</i>
14:30	Drugs, Sex and Gambling: How to Approach Impulse Control Disorders in Parkinson's Disease K. Ray Chaudhuri <i>United Kingdom</i>	14:30	Peripheral Mechanisms of Movement Disorders Con Yiannikas <i>Australia</i>
15:00	Psychosis in Parkinson's Disease: Is it a Serious Problem or is it Over-Rated? Hubert Fernandez <i>USA/Philippines</i>	15:00	Movement Disorders Due to Nerve Hyper Excitability Kimi Yoshi Arimura <i>Japan</i>
15:30	The Latest Developments in Cognitive Impairment in Parkinson's Disease Andrew Evans <i>Australia</i>	15:30	Movement Disorders in Mitochondrial Disease Carolyn Sue <i>Australia</i>
Recommended Audience: Basic scientists, Clinical academicians, Health Professionals (Non-physician), Practitioners, Students/Residents/Trainees		Recommended Audience: Clinical academicians, Health Professionals (Non-physician), Practitioners, Students/Residents/Trainees	
At the conclusion of this session, participants should be better able to:		At the conclusion of this session, participants should be better able to:	
<ol style="list-style-type: none"> 1. Recognize how to screen, detect, evaluate and treat impulse control disorders in Parkinson's disease 2. Recognize and treat psychosis in Parkinson's disease 3. Recognize new developments in the recognition and treatment of cognitive impairment in Parkinson's disease 		<ol style="list-style-type: none"> 1. Utilize an efficient bedside examination in the evaluation of muscle cramps and spasms 2. Identify neuropathic and myopathic causes of movement disorders 3. Recognize movements arising from mitochondrial diseases 	



5th AOPMC Scientific Program

Sunday, March 13, 2016, *continued*

3306	Parallel Session	3407	Parallel Session
	Atypical Parkinsonism 14:30 – 16:00		Neuromodulation in Parkinson's Disease and Other Movement Disorders: The Good, the Bad and the Ugly 16:30 – 18:00
Location:	VIP West, Third Floor	Location:	Executive Room 11 and 12, Second Floor
Chairs:	Leonardo Fugoso <i>USA</i> Ryosuke Takahashi <i>Japan</i>	Chairs:	Praween Lolekha <i>Thailand</i> Yasushi Shimo <i>Japan</i>
14:30	When it is NOT Parkinson's Disease: Clinical Spectrum of Atypical Parkinsonisms Louis Tan <i>Singapore</i>	16:30	Neuromodulation in Parkinson's Disease: How Does it Really Work? Simon Lewis <i>Australia</i>
15:00	The Role of Imaging and Other Modalities in Atypical Parkinsonism Roongroj Bhidayasiri <i>Thailand</i>	17:00	Perils and Pitfalls of Neuromodulation in Parkinson's Disease Genko Oyama <i>Japan</i>
15:30	Management of Atypical Parkinsonism Mandy Au-Yeung <i>Hong Kong</i>	17:30	The Expanding Role of Neuromodulation in other Movement Disorders Sun Ha Paek <i>Korea</i>
Recommended Audience: Clinical academicians, Health Professionals (Non-physician), Practitioners, Students/Residents/Trainees		Recommended Audience: Clinical academicians, Health Professionals (Non-physician), Practitioners, Students/Residents/Trainees	
At the conclusion of this session, participants should be better able to:		At the conclusion of this session, participants should be better able to:	
<ol style="list-style-type: none">1. Recognize and describe the clinical presentations of various atypical parkinsonian syndromes2. Integrate the emerging role of imaging modalities in the diagnosis of atypical parkinsonian syndromes3. Identify the treatment options of the most common atypical parkinsonian disorders		<ol style="list-style-type: none">1. Describe the physiological basis of neuromodulation2. Assess the benefits, possible side effects and long term outcome of neuromodulation3. Identify other movement disorders that may benefit from neuromodulation	

5th AOPMC Scientific Program

Sunday, March 13, 2016, *continued*

3408	Parallel Session
	Sleep Disturbances in Parkinson's Disease and Other Movement Disorders 16:30 – 18:00
Location:	VIP West, Third Floor
Chairs:	Maria Victoria Alvarez <i>USA</i> Win Min Thit <i>Myanmar</i>
16:30	Idiopathic IRBD (Idiopathic REM Sleep Behavioral Disorder) and Parkinson's Disease Jee-Young Lee <i>Korea</i>
17:00	Medical Management of Sleep Disturbances in Parkinson's Disease Tim Anderson <i>New Zealand</i>
17:30	Addressing the Most Common Movement Disorder: Update on Restless Leg Syndrome Thomas Kimber <i>Australia</i>
Recommended Audience: Clinical academicians, Health Professionals (Non-physician), Practitioners, Students/Residents/Trainees	
At the conclusion of this session, participants should be better able to:	
<ol style="list-style-type: none"> 1. Define the characteristics of IRBD and Parkinson's disease 2. Identify the treatment options of the most common sleep disorders in Parkinson's disease and other movement disorders 3. Integrate the latest developments in the understanding and treatment of restless legs syndrome 	

3409	Parallel Session
	Subclinical Parkinson's Disease: Past, Present and Future 16:30 – 18:00
Location:	Ballroom AB, Second Floor
Chairs:	Shengdi Chen <i>People's Republic of China</i> Taku Hatano <i>Japan</i>
16:30	Biomarkers of Neurodegeneration Baorong Zhang <i>People's Republic of China</i>
17:00	Pathophysiologic Basis of Neurodegeneration Piu Bill Chan <i>People's Republic of China</i>
17:30	Parkinson's at Risk Syndrome (PARS) and Prodromes Yih-Ru Wu <i>Taiwan</i>
Recommended Audience: Clinical academicians, Health Professionals (Non-physician), Practitioners, Students/Residents/Trainees	
At the conclusion of this session, participants should be better able to:	
<ol style="list-style-type: none"> 1. Recognize how biomarkers help in our understanding of neurodegenerative diseases 2. Integrate our understanding of neurodegeneration from the pathophysiologic standpoint 3. Identify the range of clinical markers of early/prodromal Parkinson's disease 	



Faculty List

Alvarez, Maria Victoria, <i>USA</i>	3408	Kobayashi, Shunsuke, <i>Japan</i>	2101
Anderson, Tim, <i>New Zealand</i>	3408	Lee, Jee-Young, <i>Korea</i>	3408
Arimura, Kimiyoshi, <i>Japan</i>	3305	Lee, Lillian, <i>Philippines</i>	3101
Au-Yeung, Mandy, <i>Hong Kong</i>	3306	Lewis, Simon, <i>Australia</i>	1103, 3407
Bajwa, Jawad A., <i>Saudi Arabia</i>	2101	Lim, Erle Chuen-Hian, <i>Singapore</i>	2305
Behari, Madhuri, <i>India</i>	2306	Lim, Shen-Yang, <i>Malaysia</i>	1105, 1106, 2409
Bhatt, Mohit, <i>India</i>	2306	Lim, Thien Thien, <i>Malaysia</i>	2306
Bhidayasiri, Roongroj, <i>Thailand</i>	1105, 3306	Lolekha, Praween, <i>Thailand</i>	3407
Bohlega, Saeed, <i>Saudi Arabia</i>	2101	Miyasaki, Janis, <i>Canada</i>	2304, 3102
Buhat, Donna, <i>Philippines</i>	1103	Mizuno, Yoshikuni, <i>Japan</i>	2408
Chan, Piu Bill, <i>People's Republic of China</i>	2203, 3409	Mok, Vincent, <i>People's Republic of China</i>	1106
Chaudhuri, K. Ray, <i>United Kingdom</i>	3304	Murata, Miho, <i>Japan</i>	2408
Chen, Jou-Hsien, <i>Taiwan</i>	2101	Ng, Arlene, <i>Philippines</i>	3305
Chen, Shengdi, <i>People's Republic of China</i>	3409	Nomoto, Masahiro, <i>Japan</i>	2304
Constantino, Anne, <i>USA</i>	2304	Okuma, Yasuyuki, <i>Japan</i>	2407
Diesta, Cid, <i>Philippines</i>	2407	Oyama, Genko, <i>Japan</i>	3407
Evans, Andrew, <i>Australia</i>	1104, 1105, 3304	Paek, Sun Ha, <i>Korea</i>	3407
Fernandez, Hubert, <i>USA/Philippines</i>	2304, 3304	Piano, Anthony, <i>Philippines</i>	2409
Fugoso, Jr., Leonardo, <i>USA</i>	3306	Poewe, Werner, <i>Austria</i>	2203, 2306
Funayama, Manabu, <i>Japan</i>	2102	Rosales, Raymond, <i>Philippines</i>	1101, 1102, 2407, 3101
Fung, Victor, <i>Australia</i>	2408	Sakakibara, Ryuji, <i>Japan</i>	2409
Gershanik, Oscar, <i>Argentina</i>	2101	Shang, Hui Fang, <i>People's Republic of China</i>	3304
Goyal, Vinay, <i>India</i>	1103, 3102	Shimo, Yasushi, <i>Japan</i>	3407
Gracies, Jean-Michel, <i>France</i>	1101, 2407	Snow, Barry, <i>New Zealand</i>	2305
Hanajima, Ritsuko, <i>Japan</i>	3305	Sue, Carolyn, <i>Australia</i>	1104, 3305
Hatano, Taku, <i>Japan</i>	3409	Susatia, Frandy, <i>Indonesia</i>	2306
Hattori, Nobutaka, <i>Japan</i>	1102, 2102, 3101	Taira, Takaomi, <i>Japan</i>	2305
Hernandez Franco, Jorge, <i>Mexico</i>	3102	Takahashi, Ryosuke, <i>Japan</i>	3306
Huang, Ying-Zu, <i>Taiwan</i>	2305	Tan, Eng-King, <i>Singapore</i>	1102, 2102, 3101
Ibrahim, Norlinah, <i>Malaysia</i>	2409	Tan, Louis, <i>Singapore</i>	3306
Jamora, Roland Dominic, <i>Philippines</i>	1106, 2203, 3102	Thit, Win Min, <i>Myanmar</i>	3408
Jeon, Beom, <i>Korea</i>	2409	Thompson, Philip, <i>Australia</i>	2101
Kaji, Ryuji, <i>Japan</i>	2408	Ugawa, Yoshikazu, <i>Japan</i>	2408
Kanovsky, Petr, <i>Czech Republic</i>	2407	Wu, Ruey-Meei, <i>Taiwan</i>	2102
Kim, Hee-Tae, <i>Korea</i>	2305	Wu, Yih-Ru, <i>Taiwan</i>	3409
Kim, Jae Woo, <i>Korea</i>	3304	Yamamoto, Mitsutoshi, <i>Japan</i>	3102
Kimber, Thomas, <i>Australia</i>	1104, 3408	Yiannikas, Con, <i>Australia</i>	3305
Klein, Christine, <i>Germany</i>	2102	Zhang, Baorong, <i>People's Republic of China</i>	3409

Poster Session Schedule

*A listing of the abstracts by topic is found on pages 33-43.

Saturday, March 12, 2016

Poster Session: 11:30 – 12:30

Poster Viewing: 8:00 – 18:00

Location: Marriott Grand Ballroom, Ground Floor Foyer

	Poster #
Huntington's disease	1-5
Parkinsonism (secondary and parkinsonism-plus).	6-26
Parkinson's disease: Clinical Trials.	27-42
Parkinson's disease: Electrophysiology.	43-47
Parkinson's disease: Neuropharmacology	48-57
Parkinson's disease: Neurorehabilitation	58-65
Parkinson's disease: Non-motor phenotypes.	66-94
Parkinson's disease: Phenomenology	95-97
Parkinson's disease: Quality of Life/Caregiver burden.	98-106
Parkinson's disease: Rating scales.	107-111
Surgical Therapy: Parkinson's disease	112-116

Sunday March 13, 2016

Poster Session: 11:30 – 12:30

Poster Viewing: 8:00 – 18:00

Location: Marriott Grand Ballroom, Ground Floor Foyer

	Poster #
Ataxia	117-120
Basic Science	121-153
Choreas (non-Huntington's disease)	154-155
Drug-Induced Movement Disorders	156-158
Dystonia	159-168
Epidemiology.	169-177
Genetics	178-187
Lewy Body Dementia and other dementias in movement disorders.	188
Myoclonus	189-191
Neuroimaging	192-201
Neuropharmacology	202-207
Neurorehabilitation in Dystonia.	208
Other movement disorders	209-213
Pediatric Movement disorder.	214-216
Quality of life/caregiver burden in movement disorders.	217
Restless legs syndrome	218-220
Spasticity	221-223
Surgical Therapy: Other Movement Disorders	224-225
Tremor	226-230
Wilson's disease, storage and metabolic movement disorders	231-233



Guided Poster Tours

Guided Poster Tours will take place during the regular poster sessions on March 12 – 13, 2016. They will be led by members of the AOPMC faculty and the authors will be present to discuss the abstracts. There will be ten total Guided Poster Tours with five simultaneous tours per day on Saturday, March 12 and Sunday, March 13. Anyone is welcome to attend; please meet at the first poster of the tour at the start time. Each tour will highlight exceptional posters.

The MDS-AOS would like to acknowledge Aguetant for their support of the Guided Poster Tours through an unrestricted grant.

Saturday, March 12, 2016

11:30 – 12:30

Location: Marriott Grand Ballroom, Ground Floor Foyer

Guided Poster Tour 1: Parkinson's Disease: Rating Scales Parkinson's Disease: Clinical Trials Parkinson's Disease: Surgery

Tour Leader: Hubert Fernandez

Posters featured in this tour:

Poster #	Title
27	Immune response mediators as a factor of Parkinson's disease
35	Determining the driving ability of Parkinson's disease patients and controls by using a computer-based 3D driving simulator.
38	123-I-Ioflupane SPECT in combination with MIBG myocardial scintigraphy in Parkinson's disease: A case study.
39	The overview of the Japan Parkinson's Progression Markers Initiative (J-PPMI)
40	The relationship among 123I-FP-CIT scintigraphy, 123I-MIBG cardiac scintigraphy, and olfactory function tests in Parkinson's disease
107	Parkinson's disease risk score (PDRS) for Parkinson's disease screening in aging population: Effect of yoga and meditation
110	A novel patient diary for assessment of motor fluctuations and drug efficacy in Parkinson's disease
115	Impulse control disorders in Parkinson's disease - Impact of deep brain stimulation and other factors

Guided Poster Tour 2: Parkinson's Disease: Quality of Life/Caregiver Burden Parkinson's Disease: Neurorehabilitation

Tour Leader: Anthony Piano

Posters featured in this tour:

Poster #	Title
58	Risk and adverse outcomes of fractures in patients with Parkinson's disease: two nationwide studies
60	The effect of the pilates method on the motor symptoms, depression and quality of life of Filipino patients
61	The relationship between body composition and postural instability in people with idiopathic Parkinson's disease
63	Effect of Gait and Balance training on Parkinson's Disease Patients after Bilateral STN-DBS
101	Levodopa-Carbidopa Intestinal Gel: The naso-jejunal phase, a redundant convention?
102	Influence of tremor on quality of life of patients with Parkinson disease
103	Increased risk of depression in patients with Parkinson's disease: A nationwide cohort study
104	Fall and near fall risks in ambulatory Filipino patients with Parkinson's disease
106	Non-motor features among motor subtypes in newly diagnosed Parkinson's disease patients: a cohort study from Southwest China

Guided Poster Tours

Saturday, March 12, 2016, *continued*

Guided Poster Tour 3: Parkinson's Disease: Neuropharmacology

Tour Leader: Raymond Rosales

Posters featured in this tour:

Poster #	Title
48	The role of orexin in Parkinson's disease: A review of article
50	Dopaminergic therapy: on a number of complications as increasing of libido in patients with Parkinson's disease and Parkinson's syndrome
51	Combined levodopa carbidopa with Entacapone improves the motor complications in advanced parkinson disease
52	Neuroprotective effect of apocyanin, a NADPH oxidase inhibitor in lipopolysaccharide induced Parkinson's disease model
55	Novel HDAC1/2 isoform-specific inhibitor K560 ameliorates MPP+/MPTP-mediated experimental Parkinson's disease
56	Efficacy and tolerability of levetiracetam in the management of levodopa-induced dyskinesia in Parkinson's disease: A meta-analysis
57	The efficacy and safety of Zonisamide as adjunctive therapy in Parkinson's disease: a meta-analysis

Guided Poster Tour 4: Parkinson's Disease: Non-Motor Phenotypes

Tour Leader: Mandy Au-Yeung

Posters featured in this tour:

Poster #	Title
69	Non-motor symptoms in Parkinson's patients: The PALS (Early Parkinson's Disease Longitudinal Singapore) study
71	Orthostatic hypotension and cardiac sympathetic denervation in Parkinson's disease patients with REM sleep behavioral disorder
75	Lateral Geniculate Atrophy in Parkinson's with Visual Hallucination
76	Apathy and striatal dopamine defects in non-demented patients with Parkinson's disease
79	Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson's disease
81	Assessment of motor imaginary of gait by Timed Up&Go test and cognitive impairment in Parkinson's disease
86	Progression of non-motor symptoms in Parkinson's disease among different age populations: A two year follow-up study
87	Retinal nerve fiber layer thinning: A window into rapid eye movement sleep behavior disorders in Parkinson's disease
93	A gene for risk taking: Effect of genotypic variants on decision making and impulsivity in Parkinson's disease

Guided Poster Tour 5: Parkinsonism

Tour Leader: Jawad A. Bajwa

Posters featured in this tour:

Poster #	Title
7	Parkinsonian signs in patients with Alzheimer's disease is not correlated with white matter hyperintensity: a Korean study
10	Coronary artery disease in patients with Parkinsonism syndrome with/without type 2 diabetes
16	Levodopa responsive secondary Parkinsonism in the setting of postero reversible encephalopathy syndrome in the postpartum period
18	Comparison of cognitive symptoms in Parkinson's disease and Parkinson plus syndrome
23	Clinical and polysomnographic features correlates to sleep-disordered breathing in Multiple System Atrophy
24	The pathological impact of oligodendrocyte lineage cells on multiple system atrophy
25	Proteomic and Interleukin-6 (IL6), estrogen receptor beta (ESR2) gene mutation analysis in Parkinson's disease (PD)



Guided Poster Tours

Sunday, March 13, 2016

11:30 – 12:30

Location: Marriott Grand Ballroom, Ground Floor Foyer

Guided Poster Tour 6: Basic Science

Tour Leader: Carolyn Sue

Posters featured in this tour:

Poster #	Title
122	Generation of naivetropic Induced pluripotent stem cells from Parkinson's disease patients for high efficiency genetic manipulation
124	Alternative mitophagy suppresses the development of Parkin-related Parkinson's disease
125	Forebrain-specific knockout of ESCRT-0/Hrs disrupts protein quality control and facilitates ER stress-mediated neurodegeneration via apoptotic and necroptotic pathways
134	The serum response factor SRF protect dopamine (DA) neurons in Parkinson's disease Partially by mediate autophagy
143	Parkinson's disease-associated mutations of PLA2G6 alters the membrane dynamics.
147	Immunohistochemical study of astrocytic markers in parkin mutations
152	Does endogeneous alpha-synuclein have protective property in human alpha-synuclein transgenic models?

Guided Poster Tour 7: Genetics

Epidemiology

Tour Leader: Baorong Zhang

Posters featured in this tour:

Poster #	Title
172	Medical expenditure for patients with Parkinson's disease: A nationwide population-based study
173	Prospective cohort study in patients with early gastric cancer for detection of prodromal Parkinson's disease (EGC-PPD): Study rationale and protocol
175	12-year review of a Movement Disorders database in Singapore
177	Epidemiology of Parkinson's disease among Uzbek population Epidemiology
180	Association of the DRD2 (CA)n and DRD3 Ser9Gly polymorphisms with Parkinson's disease and response to dopamine agonists Genetics
184	Genome-wide association studies in X-linked Dystonia-Parkinsonism
185	Relationship between Alzheimer's disease GWAS-linked top hits and risk of Parkinson's disease with or without cognitive decline: A Chinese population-based study
187	Whole-genome sequencing and genome-wide expression profiling converge on TAF1 as a dysfunctional gene in X-linked dystonia-parkinsonism (DYT3, "Lubag")

Guided Poster Tour 8: Non-Parkinson's Disease Related and Other Movement Disorders

Tour Leader: Cid Diesta

Posters featured in this tour:

Poster #	Title
220	Restless bladder in an elderly woman: an unusual variant of restless legs syndrome
117	Spinocerebellar Ataxia 6 in Eastern India: Some new observations
119	Association study between CAG repeats of PolyQ-related genes and SCA3/MJD
213	Cognitive profile of Filipino patients with X-linked dystonia parkinsonism
222	Passive ROM rehabilitation immediately following botulinum toxin injection improves outcome in post-stroke spasticity
226	Essential tremor in patients with Parkinson's disease
229	Cardiovascular autonomic dysfunctions in essential tremor
230	Effect of zonisamide on post-traumatic Holmes' tremor

Guided Poster Tours

Sunday, March 13, 2016, *continued*

Guided Poster Tour 9: Neuropharmacology Neurophysiology Neuroimaging

Tour Leader: Yih-Ru Wu

Posters featured in this tour:

Poster #	Title
201	Clinical correlates of striatal dopamine transporter binding in Parkinson's disease
194	Regional change in glucose metabolism of essential tremor
195	Cerebral perfusion SPECT for Early detection of subjective memory impairment in Parkinson's disease
196	The prevalence and risk factors of cerebral microbleeds in patients with Parkinson's disease
200	Disrupted functional connectivity in Parkinson's disease patients with severe olfactory dysfunction
205	Effect of nicotine on the pharmacokinetics of levodopa
206	Neuroprotective effect of Co enzyme Q10 against cognitive deficits associated with sleep deprivation and sleep debt: Possible role of oxidative stress, mitochondrial dysfunction and neuroinflammatory cascades

Guided Poster Tour 10: Dystonia Drug-induced Movement Disorders Dementia

Tour Leader: Yoshikazu Ugawa

Posters featured in this tour:

Poster #	Title
160	Validation of a screening questionnaire for X-linked Dystonia Parkinsonism (XDP): The first phase of the population based prevalence study of XDP in Panay
163	Prevalence and clinical characteristics of golfer's yips in Japan
164	Altered inter-hemispheric functional coordination in primary blepharospasm
165	Outcomes of bilateral pallidal deep brain stimulation in five patients with X-Linked Dystonia Parkinsonism (DYT3)
167	Validation of the proposed XDP-MDSP rating scale for the evaluation of patients with X-linked dystonia-parkinsonism (XDP)
168	Neuropsychiatric comorbidity and quality of life in Oromandibular Dystonia
208	Efficiency criteria of correction dystonia in stages of neurorehabilitation



Abstract Listing by Topic

Posters 1 – 116 will be presented on Saturday, March 12, 2016 from 11:30 – 12:30.

Huntington's disease

- 1** A case of misdiagnosed Huntington's disease: Acanthocytes in a patient with Huntington's disease
FNU Ohnmar (Yangon, Myanmar)
- 2** Protective effect of spermidine against 3-NP induced neurotoxicity in rats: possible antioxidant and anti-inflammatory mechanism
Sumit Jamwal, Puneet Kumar (Moga, India)
- 3** Withdrawn by author
- 4** Neuroprotective potential of anti-oxidant potent fractions from *Convolvulus pluricaulis* Choisy. in 3-Nitropropionic acid challenged rats
Atish Prakash, Mandeep Kaur, AN Kalia, Abu Bakar Majeed (Selangor, Malaysia)

Parkinsonism (secondary and parkinsonism-plus)

- 6** Plethora of Parkinson's disease - Oral health considerations with role of dentist
Suraj Agarwal (Agra, India)
- 7** Parkinsonian signs in patients with Alzheimer's disease is not correlated with white matter hyperintensity: a Korean study
Oh Dae Kwon (Daegu, Korea)
- 8** Withdrawn by author
- 9** The importance of Ishihara Testing in early diagnosing of Parkinson disease
Sanjar Mirdedaev (Namangan Region, Uzbekistan)
- 10** Coronary artery disease in patients with Parkinsonism syndrome with/without type 2 diabetes
Evgenia Shalaeva, Bakhtiyor Janabaev, Quvondiq Matmurotov, Ulugbek Kasimov, Azam Bobabekov (Tashkent, Uzbekistan)
- 11** Withdrawn by author
- 12** Mild Parkinsonian signs in patients with cognitive dysfunction
Jinyoung Ahn, Seok-Jae Kang, Hee-Tae Kim (Seoul, Korea)
- 13** To evaluate Molecular mechanisms associated with Manganese (Mn) induced neurotoxicity in cell and animal models: A transcriptomics approach
Raghunath Reddy, Rajeswara Mythri, Srinivas Bharath M M (Bangalore, India)
- 14** A comparison of depressive symptoms and sleep disturbances in individuals with Parkinson's disease and Parkinson plus syndrome
Rohit Verma, Kuljeet Anand (New Delhi, India)
- 15** CSF1R mutations presenting with atypical Parkinsonism
Jae Hyeok Lee, Jin-Hong Shin, Gi Yeong Huh, Eun Joo Kim (Yongsan-si, Korea)
- 16** Levodopa responsive secondary parkinsonism in the setting of posterior reversible encephalopathy syndrome in the postpartum period
Devangi Desai, Soham Desai (Anand, India)
- 17** Withdrawn by author
- 18** Comparison of cognitive symptoms in Parkinson's disease and Parkinson plus syndrome
Shaily Mina, Kuljeet Anand (New Delhi, India)
- 19** Hallervorden Spatz (case report)
Maseumeh Dashti (Isfahan, Iran)
- 20** Unusual phenotype of pathologically confirmed progressive supranuclear palsy with autonomic dysfunction and cerebellar ataxia
Katerina Mensikova, Lucie Tuckova, Jiri Ehrmann, Petr Kanovsky (Olomouc, Czech Republic)
- 21** Withdrawn by author
- 22** Non-motor symptoms in progressive supranuclear palsy
Ruwei Ou, Wei Song, Qianqian Wei, Bei Cao, Ke Chen, Yanbing Hou, Bi Zhao, HuiFang Shang (Chengdu, Peoples Republic of China)
- 23** Clinical and polysomnographic features correlates to sleep-disordered breathing in Multiple System Atrophy
Bei Cao, Ruwei Ou, Qian-qian Wei, Tao Hu, Bi Zhao, Hui-Fang Shang (Chengdu, Peoples Republic of China)
- 24** The pathological impact of oligodendrocyte lineage cells on multiple system atrophy
Seiji Kaji, Takakuni Maki, Ryosuke Takahashi (Kyoto, Japan)
- 25** Proteomic and Interleukin-6 (IL6), estrogen receptor beta (ESR2) gene mutation analysis in Parkinson's disease (PD)
Vellingiri Balachandar, Keshavarao Sasikala (Coimbatore, India)
- 26** Gait manifestations in acquired hepatolenticular degeneration: A case report and a review of the literature
Karn Saksornchai, Suporn Travanichakul, Jirada Sringean, Onanong Jitkritsadakul, Roongroj Bhidayasiri (Bangkok, Thailand)

Parkinson's disease: Clinical Trials

- 27** Immune response mediators as a factor of Parkinson's disease
Elvina Giyazitdinova, Elvina Giyazitdinova, Yulduz Musayeva, Gulnora Rakhmibayeva (Tashkent, Uzbekistan)

Abstract Listing by Topic

Posters 1 – 116 will be presented on Saturday, March 12, 2016 from 11:30 – 12:30.

- 28** Incidence of elevated lipid metabolism in patients with Parkinson's disease
Elvina Giyazitdinova, Elvina Giyazitdinova, Yulduz Musayeva, Gulnora Rakhmibayeva (Tashkent, Uzbekistan)
 - 29** The role and value of protein S100B in the blood serum of Parkinson's disease
Rustambek Matmurodov, Khanifa Khalimova, Nilufar Rashidova (Tashkent, Uzbekistan)
 - 30** Roles of combined functional catechol-O-methyltransferase genotypes in Chinese Parkinson's disease: a cross-sectional survey
Yiwei Qian, Xiaodong Yang, Shaoqing Xu, Jiujiang Liu, Qin Xiao (Shanghai, Peoples Republic of China)
 - 31** Withdrawn by author
 - 32** Withdrawn by author
 - 33** Clinical benefits and optimal dosage of istradefylline in Parkinson's disease
Tetsuya Maeda, Tomomi Shinoda, Rena Muraoka, Miki Sugawara (Akita, Japan)
 - 34** Neuropsychological profile of patients with Parkinson's disease in Singapore
Jing Xu, Leonard Yeo, Christopher Chen, Raymond Seet, Erle Lim, YanHong Dong (Singapore)
 - 35** Determining the driving ability of Parkinson's disease patients and controls by using a computer-based 3D driving simulator
Onanong Jitkritisadaku, Soradech Krootjohn, Chusak Thanawattano, Chanawat Anan, Roongroj Bhidayasiri (Bangkok, Thailand)
 - 36** Levodopa improves fatigue only in PD patients with mild or no depression
Rao Fu, Xiaoguang Luo (Shenyang, Peoples Republic of China)
 - 37** Patients with Parkinson disease and vascular parkinsonism have lower urinary tract dysfunction and nocturnal polyuria, which can be ameliorated by amantadine
Tomoyuki Uchiyama, Tatsuya Yamamoto, Taro Kadowaki, Keisuke Suzuki, Tomonori Yamanishi, Ryuji Sakakibara, Satoshi Kuwabara, Koichi Hirata (Shimotsuga-gun, Tochigi, Japan)
 - 38** 123-I-Ioflupane SPECT in combination with MIBG myocardial scintigraphy in Parkinson's disease: A case series study
Akane Yamada, Takenobu Murakami, Yoichiro Ikuni, Akeshi Morimatsu, Akiko Shirata, Hiroshi Ito, Yoshikazu Ugawa, Kiyomi Yamane (Koriyama City, Japan)
 - 39** The overview of the Japan Parkinson's Progression Markers Initiative (J-PPMI)
Yohei Mukai, Hirohisa Watanabe, Hideki Mochizuki, Nobutaka Hattori, Ryosuke Takahashi, Miho Murata (Tokyo, Japan)
 - 40** The relationship among 123I-FP-CIT scintigraphy, 123I-MIBG cardiac scintigraphy, and olfactory function tests in Parkinson's disease
Junya Ebina, Akiko Shinya, Kosei Hirata, Hisao Kitazono, Teruhiko Sekiguchi, Makoto Takahashi, Akira Inaba, Satoshi Orimo (Tokyo, Japan)
 - 41** Attenuation of antecollis increases the blood concentration level of the levodopa in patients with the Parkinson's disease and related disorders
Hiroyuki Todo, Yuji Saitoh, Shoko Watanabe, Yohei Mukai, Takashi Sakamoto, Miho Murata (Kodaira, Japan)
 - 42** A Meta-Analysis on Safinamide as Add-on Therapy to Dopamine Agonist in Early Stage Parkinson's disease
Gerard Raimon Saranza, Katrina Remigio, Ela Barcelon, Roland Dominic Jamora (Manila, Philippines)
- Parkinson's disease: Electrophysiology**
- 43** Interplay between alpha and theta during working memory in patients with Parkinson's disease
Anita Pal, Madhuri Behari, Ratna Sharma (New Delhi, India)
 - 44** Ocular motor disorders and saccadic eye movements among adult Filipino Parkinson's disease patients seen in a tertiary hospital
Anna Kharima Mindalano, Anna Lorena Chan, Criscely Go, Erwin Palisoc (Manila, Philippines)
 - 45** Central cholinergic dysfunction could be associated with oropharyngeal dysphagia in early Parkinson's disease
Wooyoung Jang (Gangneung, Korea)
 - 46** Different changes in brain activities limited to certain regions related to mild cognitive impairment in early-onset and late-onset nondemented Parkinson's disease patients
Xuetao He, Lijuan Wang, Yuhu Zhang, Jiuling Chen (Guangzhou, Peoples Republic of China)
 - 47** Peripheral Neuropathy in Parkinson's disease
Kuljeet Anand, Prashant Kumar, Jyoti Garg (Delhi, India)
- Parkinson's disease: Neuropharmacology**
- 48** The role of orexin in Parkinson's disease: A review of article
Mehri Salari (Isfahan, Iran)



Abstract Listing by Topic

Posters 1 – 116 will be presented on Saturday, March 12, 2016 from 11:30 – 12:30.

- 49** Parkinson's disease treatment as a factor of cardiac pathology
Elvina Giyazitdinova, Elvina Giyazitdinova, Yulduz Musayeva (Tashkent, Uzbekistan)
- 50** Dopaminergic therapy: on a number of complications as increasing of libido in patients with Parkinson's disease and Parkinson's syndrome
Sanjar Mirdedaev (Namangan Region, Uzbekistan)
- 51** Combined levodopa carbidopa with Entacapone improves the motor complications in advanced Parkinson's disease
Md. Ashraf Ali (Dhaka, Bangladesh)
- 52** Neuroprotective effect of apocyanin, a NADPH oxidase inhibitor in lipopolysaccharide induced Parkinson's disease model
Bimla Nehru (Chandigarh, India)
- 53** Withdrawn by author
- 54** Effects of Single Lipopolysaccharide Preconditioning on Rat model for Parkinson's disease
Mojtaba Golpich, Elham Amini, Zahurin Binti Mohamed, Raymond Azman Ali, Norlinah Ibrahim, Abolhassan Ahmadiani (Petaling Jaya, Malaysia)
- 55** Novel HDAC1/2 isoform-specific inhibitor K560 ameliorates MPP+/MPTP-mediated experimental Parkinson's disease
Chi-Jing Choong, Tsutomu Sasaki, Hideki Hayakawa, Toru Yasuda, Kousuke Baba, Yoshiyuki Hirata, Shinichi Uesato, Hideki Mochizuki (Osaka, Japan)
- 56** Efficacy and tolerability of levetiracetam in the management of levodopa-induced dyskinesia in Parkinson's disease: A meta-analysis
Virulo Marianito, Anthony Piano, Artemio Roxas (Pasig City, Philippines)
- 57** The efficacy and safety of Zonisamide as adjunctive therapy in Parkinson's disease: a meta-analysis
Katrina Remigio, Gerard Raimon Saranza, Roland Dominic Jamora (Manila, Philippines)
- Parkinson's disease: Neurorehabilitation**
- 58** Risk and adverse outcomes of fractures in patients with Parkinson's disease: Two nationwide studies
Yi-Chun Chou, Chien-Chang Liao (Taichung, Taiwan)
- 59** Withdrawn by author
- 60** The Effect of the Pilates method on the motor symptoms, depression and quality of life of Filipino patients with Parkinson's disease
Juan Miguel Bautista, Arlene Ng, Rosemarie Malla-ao (Quezon City, Philippines)
- 61** The relationship between body composition and postural instability in people with idiopathic Parkinson's disease
Abdulkareem Diab, Leigh Hale (Baghdad, Iraq)
- 62** Gait-Aid for Freezing Gait of Parkinson's disease
Ho-Won Lee, Kyunghun Kang, Pan-Woo Ko (Gainesville, FL, USA)
- 63** Effect of gait and balance training on Parkinson's disease patients after Bilateral STN-DBS.
Venkata Padma Kagita, Rupam Borgohain, Rukmini Kandadai, Aneel Puligopu, Naveen Balne (Hyderabad, India)
- 64** Withdrawn by author
- 65** Screening of Vitamin D receptor (VDR) and Dopamine beta hydroxylase gene polymorphism and susceptibility to Parkinson's disease in South Indian Population
Dhivya Venkatesan (Chennai, India)
- Parkinson's disease: Non-motor phenotypes**
- 66** Prevalence and associations for depression in patients with Parkinson's disease: A Sri Lankan experience
Tharuka Herath, Milinda Withana, Chathuraka Rodrigo, Ranjanie Gamage, Chanika Gamge (Kandy, Sri Lanka)
- 67** Validation of the Seoul-instrumental activity daily living in the detection of dementia in Parkinson disease
Sang Jin Kim, Eun Joo Chung (Busan, Korea)
- 68** CLinical correlates of depression and anxiety in patients with Parkinson's disease
Hasmik Hambardzumyan, Hovhannes Manvelyan (Yerevan, Armenia)
- 69** Non-Motor Symptoms in Parkinson's patients: the PALS (Early Parkinson's Disease Longitudinal Singapore) Study
Samuel Ng, Hannah Heng, Zheyu Xu, Kay Yaw Tay, Wing Lok Au, Louis Tan (Singapore)
- 70** Food-induced rhinorrhea in Parkinson's disease
Osamu Kano, Renpei Sengoku, Shigeo Murayama, Yasuo Iwasaki (Tokyo, Japan)
- 71** Orthostatic hypotension and cardiac sympathetic denervation in Parkinson disease patients with REM sleep behavioral disorder
Kwang-Soo Lee, Joong-Seok Kim (Seoul, Korea)
- 72** Degree cognitive impairment in Parkinson's disease depending on the level of protein S100B in the blood serum
Rustambek Matmurodov, Khanifa Khalimova (Tashkent City, Uzbekistan)

Abstract Listing by Topic

Posters 1 – 116 will be presented on Saturday, March 12, 2016 from 11:30 – 12:30.

- 73** Dopamine Agonists Withdrawal Syndrome in patients with Parkinson's disease in a rural movement disorders clinic in Western India
Soaham Desai, Devangi Desai (Anand, India)
- 74** Anemia precedes the onset of motor symptoms of Parkinson's disease: a population-based cohort
Chientai Hong, Lung Chan, Li Nien Chen (New Taipei City, Taiwan)
- 75** Lateral Geniculate Atrophy in Parkinson's with Visual Hallucination
Jee-Young Lee, Eun Jin Yun, Yu Kyeong Kim, Woong-Woo Lee, Beomseok Jeon (Seoul, Korea)
- 76** Apathy and striatal dopamine defects in non-demented patients with Parkinson's disease
Su Jin Chung, Jae Jung Lee, Jee Hyun Ham, Phil Hyu Lee, Young Sohn (Seoul, Korea)
- 77** Evaluation of olfactory dysfunction in Parkinson's disease in Northern Sri Lanka
Ajantha Keshavaraj, Sorubiga Kunathilagam, Gajalaksan Balachandran (Colombo, Sri Lanka)
- 78** Cognitive behavioral therapy for Japanese PD patients with depression
Issei Shinmei, Miho Murata, Masaru Horikoshi (Kodaira, Japan)
- 79** Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson's disease
Satoru Hasegawa, Sae Goto, Hirokazu Tsuji, Tatsuya Okuno, Takashi Asahara, Koji Nomoto, Akihide Shibata, Yoshiro Fujisawa, Akira Okamoto, Kinji Ohno, Masaaki Hirayama (Nagoya City, Japan)
- 80** Chin EMG variance and dream-enactment behavior during polysomnography in Parkinson's disease
Yun Shen, Kangping Xiong, Cheng Jie Mao, Chun-Feng Liu (Suzhou, Peoples Republic of China)
- 81** Assessment of motor imaginary of gait by timed up and go test and cognitive impairment in Parkinson's disease
Yasuko Kuroha, Arika Hasegawa, Takashi Tani, Nae Matsubara, Takeshi Ikeuchi, Ryoko Koike (Niigata, Japan)
- 82** The 3-second rule in Parkinson's disease: A synchronized tapping study
Shin-ichi Tokushige (Tokyo, Japan)
- 83** Withdrawn by author
- 84** Disruption of circadian rhythm function and anti-oxidation via SIRT1-BMAL1 pathway in 6-OHDA induced Parkinson's disease model
Yali Wang, Siyue Li, Chun-feng Liu (Suzhou, Peoples Republic of China)
- 85** Long-term administration of L-DOPA accelerates the disorders of circadian rhythm in 6-OHDA induced PD model
Siyue Li, Yali Wang, Chunfeng Liu (Suzhou, Peoples Republic of China)
- 86** Progression of non-motor symptoms in Parkinson's disease among different age populations: A two years follow-up study
Ruwei Ou, Jing Yang, Bei Cao, Qianqian Wei, Ke Chen, Xueping Chen, Bi Zhao, Ying Wu, Wei Song, HuiFang Shang (Chengdu, Peoples Republic of China)
- 87** Retinal nerve fiber layer thinning: a window into rapid eye movement sleep behavior disorders in Parkinson's disease
Zijiao Yang, Cheng Jie Mao, Jing Wei, Jin-ru Zhang, Yun Shen, Jie Li, Ya-ping Yang, Chunfeng Liu (Suzhou, Peoples Republic of China)
- 88** Olfaction, constipation onset time and axial impairment of Parkinson' disease: can we identify clinical phenotypes?
Yan Dai, Chunfeng Liu (Soochow, Peoples Republic of China)
- 89** Olfactory deficits in the cognitive impaired de novo patients with Parkinson's disease
Jong Sam Baik (Seoul, Korea)
- 90** The regulation of ASIC1a on dopamine release and its implication in the pathogenesis of Parkinson's disease
Jing Yang, Sha Liu, Fen Wang, Chun-feng Liu (Suzhou, Peoples Republic of China)
- 91** Predictive value of motor and non-motor symptoms for the assessment of dementia and REM sleep behavior disorders (RBD) in Parkinson's disease patients (drug naive and on medication)
Leny Mathew, Suresh Kumar, Suresh Kumar Stephan Abraham, SSK Ayyar (Pathanamthitta, India)
- 92** Classification of subtypes/phenotypes of Parkinson`s disease, a study from a tertiary teaching hospital in south India
Leny Mathew, Suresh Kumar, Suresh Kumar Stephan Abraham, SSK Ayyar (Pathanamthitta, India)
- 93** A gene for risk taking: effect of genotypic variants on decision making and impulsivity in Parkinson's disease.
Roopa Rajan, Soumya Krishnamoorthy, Syam Krishnan, Gangadhara Sarma, Asha Kishore (Kerala, India)
- 94** Subjective and Objective evaluation of bowel movement among Parkinson's disease, REM sleep behavior disorder, and control
Takashi Nomura, Kenji Nakashima (Yonago, Japan)



Abstract Listing by Topic

Posters 1 – 116 will be presented on Saturday, March 12, 2016 from 11:30 – 12:30.

Parkinson's disease: Phenomenology

- 95** Sleep disorders as a common manifestation of Parkinson's disease
Elvina Giyazitdinova, Elvina Giyazitdinova, Yulduz Musayeva (Tashkent, Uzbekistan)
- 96** Relation of CADASIL syndrome to etiology and pathogenesis of vascular Parkinsonism
Elvina Giyazitdinova, Elvina Giyazitdinova, Yulduz Musayeva (Tashkent, Uzbekistan)
- 97** Gait analysis of Parkinson's disease patients with freezing of gait
Su-Yun Lee, Sang-Myung Cheon, Jae Woo Kim (Busan, Korea)

Parkinson's disease: Quality of Life/Caregiver burden

- 98** Withdrawn by author
- 99** Parkinson's Disease and the frequent reasons for emergency admission in Metropolitan Medical Center; a 2 year retrospective study
Kenneth Wong, Criscely Go (Manila, Philippines)
- 100** Beneficial role of voice inter-relating process and OM mantra enchanting in Parkinson's disease patients in south Delhi metro population
Vinod Sharma (Delhi, India)
- 101** Levodopa-Carbidopa Intestinal Gel: The naso-jejunal phase, a redundant convention?
Nirosen Vijaratnam, Sarah Hewer, Sue Varley, Eldho Paul, Kelly Bertram, Will Lee, David Williams (Melbourne, Australia)
- 102** Influence of tremor on quality of life of patients with Parkinson disease
Ziyoda Akbarkhodjaeva, Gulnora Rakhmibayeva (Tashkent, Uzbekistan)
- 103** Increased Risk of Depression in Patients with Parkinson Disease: A Nationwide Cohort Study
Chien-Chang Liao, Fung-Chang Sung (Taipei, Taiwan)
- 104** Fall and near fall risks in ambulatory Filipino Patients with Parkinson's disease
Jemellee Cano, Raymond Rosales (Quezon City, Philippines)
- 105** Withdrawn by author
- 106** Non-motor features among motor subtypes in newly diagnosed Parkinson's disease patients: a cohort study from Southwest China
Ying Wu (Chengdu, Peoples Republic of China)

Parkinson's disease: Rating scales

- 107** Parkinson's disease risk score (PDRS) for Parkinson's disease screening in aging population: Effect of yoga and Meditation
Vinod Sharma (Delhi, India)
- 108** Prevalence of Impulse Control Disorders among Adult Filipino Patients with Idiopathic Parkinson's Disease seen at Jose R. Reyes Memorial Medical Center Preliminary Results
Jan Kristoper De Guzman, Criscely Go, Archie Yap (Manila, Philippines)
- 109** Treatment and diagnosis with the use of neuropsychological scale in patients with posttraumatic subcortical Parkinsonian dementia
Nodirjon Sokhibnazarov (Tashkent, Uzbekistan)
- 110** A novel patient diary for assessment of motor fluctuations and drug efficacy in Parkinson's disease
Masahiro Nagai, Noriko Nishikawa, Hirotaka Iwaki, Rina Ando, Hayato Yabe, Masahiro Nomoto (Ehime, Japan)
- 111** Lower bone mineral density in Patients with Parkinson's disease: a cross-sectional study from Chinese Mainland
Huimin Gao (Guangzhou, Peoples Republic of China)

Surgical Therapy: Parkinson's disease

- 112** Outcomes after non-neurological surgery in patients with Parkinson's disease: A nationwide matched cohort study
Chien-Chang Liao, Ta-Liang Chen (Taipei, Taiwan)
- 113** Valproic acid improved hypersexuality after surgery of subthalamic nucleus deep brain stimulation in a patient with Parkinson's disease: A case report.
Taro Kadowaki, Kenichi Hashimoto, Tomoyuki Uchiyama, Koichi Hirata (Mibu, Japan)
- 114** The mechanisms of the STN or the GPi stimulation to striatal neurons response.
Asuka Nakajima, Yasushi Shimo, Takayuki Jo, Takanori Uka, Nobutaka Hattori (Tokyo, Japan)
- 115** Impulse control disorders in Parkinson's disease - Impact of deep brain stimulation and other factors
Rupam Borgohain, Rukmini Kandadai, Aneel Puligopu, K Vani, Shaik Jabeen, Meena Kanikannan (Hyderabad, India)
- 116** "Uneven targets" strategy in deep brain stimulation for Parkinson's disease with unilateral dystonia
Takayuki Jo, Satoko Sekimoto, Genko Oyama, Asuka Nakajima, Yasushi Shimo, Madoka Nakajima, Atsushi Umemura, Masanobu Ito, Hajime Arai, Nobutaka Hattori (Tokyo, Japan)

Abstract Listing by Topic

Posters 117 – 233 will be presented on Sunday, March 13, 2016 from 11:30 – 12:30.

Ataxia

- 117** Spinocerebellar Ataxia 6 in Eastern India: Some new observations
Kalyan Bhattacharyya, Debabrata Pulai, Debsankar Guin, Anindita Joardar, Swarnava Ray, Atanu Biswas, Alok Pandit, Gautam Ganguly (Kolkata, India)
- 118** Clinical phenotype of patients with SCA 12.
Aakash Shetty, Pettarusp Wadia (Mumbai, India)
- 119** Association study between CAG repeats of PolyQ-related genes and SCA3/MJD
Hong Jiang, Zhao Chen, Caifa Zheng, BeiSha Tang (Changsha City, Peoples Republic of China)
- 120** Is heart less frequently involved in Indian Friedreich's ataxia patients: A genotype phenotype correlation study?
Achal Srivastava, Inder Mudila, Mohammed Faruq, Sunil Shakya, Varun Suroliya, Garima Shukla, Vinay Goyal, MV Padma, Madhuri Behari (New Delhi, India)

Basic Science

- 121** Comprehensive research on the roles of neurotransmitters in pathogenesis of Movement Disorders
Babak Khodaie (Tehran, Iran)
- 122** Generation of naivetropic induced pluripotent stem cells from Parkinson's disease patients for high efficiency genetic manipulation
Jiali Pu, Zhixing Hu, Houbao Jiang, Ping Zhong, Baorong Zhang, Jian Feng (Hangzhou, Peoples Republic of China)
- 123** Withdrawn by author
- 124** Alternative mitophagy suppresses the development of Parkin-related Parkinson's disease
Jin Sung Park, Brianada Koentjoro, Carolyn Sue (St. Leonards, Australia)
- 125** Forebrain-specific knockout of ESCRT-0/Hrs disrupts protein quality control and facilitates ER stress-mediated neurodegeneration via apoptotic and necroptotic pathways
Ryuji Oshima, Takafumi Hasegawa, Keiichi Tamai, Atsushi Takeda, Nobuyuki Tanaka, Masashi Aoki (Sendai, Japan)
- 126** Microglia P2Y₆ receptor is related to Parkinson's disease
Xiaodong Yang, Yue Lou, Xueping Wang, Guidong Liu, Yiwei Qian, Jianqing Ding, Shengdi Chen, Qin Xiao (Shanghai, Peoples Republic of China)
- 127** The activity of protein S100B in the blood serum depending on the age of patients and duration of Parkinson's disease
Rustambek Matmurodov, Khanifa Khalimova, Nilufar Rashidova (Tashkent City, Uzbekistan)
- 128** Effects of bisphenol A exposure during gestation and lactation on the emotional behavior and the content of brain neurotransmitters in rat offspring
Mridul Mishra, Versha Parcha (Dehradun, India)
- 129** The effects of different concentrations of nanoliposome on the fibrillation of alpha-synuclein
Farhang Aliakbari, Dina Morshedi, Ali Akbar Shabani, Hassan Bardania, Carolyn Sue, Amir Tayaranian Marvian, Seyed Abbas Shojaosadati, Ali Akbar Saboury (Tehran, Iran)
- 130** Methodical recommendation for experimental modeling of parkinsonian syndrome in laboratory animals under antiparkinsonian medicaments.
Djakhangir Tursunov (Tashkent, Uzbekistan)
- 131** Rotenone model of Parkinson's syndrome in experimental animals
Djakhangir Tursunov (Tashkent, Uzbekistan)
- 132** The role of cathepsin L involved in the activation of microglia and Parkinson's disease
Shaoqing Xu, Xiaodong Yang, Hui Zhang, Yiwei Qian, Qin Xiao (Shanghai, Peoples Republic of China)
- 133** Tremor model caused by oxotremorine
Eldor Kasimov (Tashkent, Uzbekistan)
- 134** The serum response factor SRF protect dopamine (DA) neurons in Parkinson's disease Partially by mediate autophagy
Xiao-yu Cheng (Suzhou, Peoples Republic of China)
- 135** Main evaluation methods of medicaments which has an antiparkinsonian activity by experimental way.
Fazliddin Dustov (Tashkent, Uzbekistan)
- 136** Evaluation of L-Dopa induced dyskinesia by scale of abnormal involuntary movements
Akmal Ikramov (Tashkent, Uzbekistan)
- 137** Decreased glucocerebrosidase enzyme activity inhibits dopamine release from SH-SY5Y cells
Yutaka Oji, Taku Hatano, Nobutaka Hattori (Tokyo, Japan)
- 138** Umbilical cord lining-derived induced pluripotent stem cells as a novel source for cell replacement therapy of Parkinson's disease
Chou Chai, Ru Ong, Cheng Zhang, Bing Chai, Li Qiu, Moogaambikai Thangaveloo, Dejie Yu, Tuck Soong, Beng Ang, Soo Tang, Li Zeng, Eng-King Tan, Toan Phan, Kah-Leong Lim (Singapore)



Abstract Listing by Topic

Posters 117 – 233 will be presented on Sunday, March 13, 2016 from 11:30 – 12:30.

- 139** The effect of HSA protein on the alpha-synuclein aggregation kinetics
Hossein Mohammad-Beigi, Dina Morshedi, Seyed Abbas Shojaosadati, Gunna Christiansen, Daniel Otzen (Tehran, Iran)
- 140** Differential developmental apoptosis and apoptotic markers in 1-Methyl-4-Phenyl 1,2,3,6-Tetrahydropyridine (MPTP) resistant and susceptible mice strains and their crossbreds
Yarreiphang Haorei, Vidyadhara D J, Trichur Raju, Phalguni Alladi (Bangalore, India)
- 141** Admixed F1 progeny of Two Mice Strains with differential susceptibility to 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) have a better Nigral Dopaminergic Phenotype
Phalguni Alladi, Vidyadhara D J, Yarreiphang Haorei, P.L. Abhilash, Trichur Raju (Bangalore, India)
- 142** Withdrawn by author
- 143** Parkinson's disease-associated mutations of PLA2G6 alters the membrane dynamics.
Akio Mori, Taku Hatano, Yuzuru Imai, Yutaka Oji, Shin-ichiro Kubo, Kei Yamamoto, Makoto Murakami, Nobutaka Hattori (Tokyo, Japan)
- 144** Withdrawn by author
- 145** The structure analysis for alpha-synuclein and Lewy bodies of Parkinson's disease patients with synchrotron radiation
Katsuya Araki, Naoto Yagi, Rie Nakatani, Hideki Hayakawa, Kousuke Baba, Yuji Goto, Hideki Mochizuki (Osaka, Japan)
- 146** Contra-directional coupling of Nur77 and Nurr1 in Neurodegeneration: A novel mechanism for Memantine-induced anti-inflammation and anti-mitochondrial impairment
Jing Zou, Xiaobo Wei, Qing Wang (Guangzhou, Peoples Republic of China)
- 147** Immunohistochemical study of astrocytic markers in parkin mutations
Masayoshi Kanou (Tokyo, Japan)
- 148** Influence of CD200 on inhibiting the inflammatory response by regulating the KATP channel of MG cells in PD mice
Min Ye (Nanjing, Peoples Republic of China)
- 149** Nur77 involved in ERstress-induced apoptosis and autophagic cell death in 6-OHDA lesioned PC12 cell
Huimin Gao (Guangzhou, Peoples Republic of China)

- 150** Withdrawn by author
- 151** Glucocerebrosidase deficiency promotes the propagation of a-synuclein pathology
Shinya Okuda, Norihito Uemura, Ryosuke Takahashi (Kyoto, Japan)
- 152** Does endogenous alpha-synuclein have protective property in human alpha-synuclein transgenic models?
Masanori Sawamura (Kyoto, Japan)
- 153** Purification of Drosophila-Omi protein from bacterial expression and production of anti-Drosophila-Omi polyclonal antibody from mouse
Saidul Islam, Md. Rahman, Hyeon Kim, Seong Hong (Jeonju, Korea)

Choreas (non-Huntington's disease)

- 154** A case of facial tics and hemichorea in human immunodeficiency virus infection with toxoplasma encephalitis
Annisa Anandatia, Ahmad Alwahdy, Darma Imran, Riwanti Estiasari (Bekasi, Indonesia)
- 155** A case report on choreiform movement following Rivastigmine Patch 13.3 mg/24 hours for Alzheimer's disease: Perspective in the Movement Disorders spectrum following use of cholinesterase inhibitors
Raymond Rosales, Maria Cristina Diaz, Julie Ann Kristy Torres (Manila, Philippines)

Drug-induced Movement Disorders

- 156** Withdrawn by author
- 157** Withdrawn by author
- 158** Tardive dyskinesia in patients with depressive disorder treated with flupentixolmelitracin - results from a 12-month, prospective, open study under naturalistic conditions in Bangladesh
Rashimul Haque, Kaniza Kabir (Dhaka, Bangladesh)

Dystonia

- 159** An unusual case of primary non-acquired Hemidystonia
Shyam Jaiswal, Muralidhar Reddy, Subhendu Parida (Hyderabad, India)
- 160** Validation of a Screening Questionnaire for X-linked Dystonia Parkinsonism (XDP): The First Phase of the Population Based Prevalence Study of XDP in Panay
Jose Danilo Diestro, Paul Matthew Pasco, Lillian Lee (Manila, Philippines)
- 161** Treatment of dystonia and tremors in Parkinson's disease
Sanjay Jaiswal (Kota, India)

Abstract Listing by Topic

Posters 117 – 233 will be presented on Sunday, March 13, 2016 from 11:30 – 12:30.

- 162** Long-term improvement of musician's and writer's focal dystonia after ventrooral thalamotomy
Takaomi Taira, Shiro Horisawa (Tokyo, Japan)
- 163** Prevalence and Clinical Characteristics of Golfer's Yips in Japan
Yasufumi Gon, Masahito Mihara, Sadahito Kawamura, Ken Nakata, Hideki Mochizuki (Suita, Japan)
- 164** Altered inter-hemispheric functional coordination in primary blepharospasm
Jing Yang, ChunYan Luo, Song Wei, Qianqian Wei, Ruwei Ou, Yanbing Hou, Bi Zhao, QiYong Gong, HuiFang Shang (Chengdu, Peoples Republic of China)
- 165** Outcomes of bilateral pallidal deep brain stimulation in 5 patients with X-Linked Dystonia Parkinsonism (DYT3)
Jose Francisco Aguilar, Theodor Vesagas, Roland Dominic Jamora, Rosalia Teleg, Lillian Lee (San Juan City, Philippines)
- 166** The Effects of Botulinum Toxin in Oromandibular Dystonia, A Meta-analysis
Ria Monica Asuncion, Raymond Rosales (Manila, Philippines)
- 167** Validation of the proposed XDP-MDSP rating scale for the evaluation of patients with X-linked dystonia-parkinsonism (XDP)
Paul Matthew Pasco, Lillian Lee, Roland Dominic Jamora, Cid Czarina Diesta, Arlene Ng, Rosalia Teleg, Criscely Go, Raymond Rosales, Hubert Fernandez (Manila, Philippines)
- 168** Neuropsychiatric comorbidity and quality of life in oromandibular dystonia
Vinay Goyal, Rai Neha, Kumar Nand, Shukla Behari (New Delhi, India)

Epidemiology

- 169** Case study of sporadic multiple system atrophy at a young age
Elvina Giyazitdinova, Elvina Giyazitdinova, Yulduz Musayeva (Tashkent, Uzbekistan)
- 170** Delayed hits and misses in the diagnosis of Parkinson's disease
Criscely Go (Manila, Philippines)
- 171** Withdrawn by author
- 172** Medical expenditure for patients with Parkinson's disease: a nationwide population-based study
Yi-Chun Chou, Chien-Chang Liao, Ta-Liang Chen (Taichung, Taiwan)

- 173** Prospective cohort study in patients with Early Gastric Cancer for detection of Prodromal Parkinson Disease (EGC-PPD): study rationale and protocol
Chae Won Shin, Han-Kwang Yang, SungHye Park, Hyuk-Joon Lee, Seonmi Kim, Woong-Woo Lee, Hyeyoung Park, Aryun Kim, Han-Joon Kim, Beomseok Jeon (Seoul, Korea)
- 174** Withdrawn by author
- 175** 12-Year Review of a Movement Disorders Database in Singapore
Irene Seah, Samuel Ng, Wei Li, Hwee Lan Ng, Kay Yaw Tay, Wing Lok Au, Louis Tan (Singapore)
- 176** Epidemiology of Parkinson's disease in Ukraine in 2014
Yevgen Trufanov, Natalia Svyrydova, Anatoliy Galusha, Oleksiy Popov, Genadiy Chupryna (Kyiv, Ukraine)
- 177** Epidemiology of Parkinson's disease among Uzbek population
Navruza Tolibova, Mukhlisa Khanova, Oybek Turgunkhujaev (Tashkent, Uzbekistan)

Genetics

- 178** LINE-1 expression and correlation with methylation status in rat brain
Somnath Mukherjee, K.C Upadhyaya, Deepak Sharma (New Delhi, India)
- 179** Role of DJ-1 promoter variants in Parkinson's disease pathogenesis
Prosenjit Pal, Tamal Sadhukhan, Shyamal Das, Kunal Ray, Jharna Ray (Kolkata, India)
- 180** Association of the DRD2 (CA)_n and DRD3 Ser9Gly polymorphisms with Parkinson's disease and response to dopamine agonists
Shaoqing Xu, Jiujiang Liu, Xiaodong Yang, Yiwei Qian, Qin Xiao (Shanghai, Peoples Republic of China)
- 181** Withdrawn by author
- 182** Analysis the relationship between behavioral and molecular genetics in stroke patients -A case control study
R. Chandirasekar, K Murugan (Coimbatore, India)
- 183** Withdrawn by author
- 184** Genome-wide association studies in X-linked Dystonia-Parkinsonism
Gerard Raimon Saranza, Aloysius Domingo, Paul Matthew Pasco, Roland Dominic Jamora (Manila, Philippines)



Abstract Listing by Topic

Posters 117 – 233 will be presented on Sunday, March 13, 2016 from 11:30 – 12:30.

- 185** Relationship between Alzheimer's disease GWAS-linked top hits and risk of Parkinson's disease with or without cognitive decline: A Chinese population-based study

Jifeng Guo, Xinxiang Yan, BeiSha Tang (Changsha, Peoples Republic of China)

- 186** Genetic identification is critical for the diagnosis of Parkinsonism: A Chinese pedigree with onset of Parkinsonism

Jifeng Guo, Lu Shen, Xinxiang Yan, BeiSha Tang (Changsha, Peoples Republic of China)

- 187** Whole-genome sequencing and genome-wide expression profiling converge on TAF1 as a dysfunctional gene in X-linked dystonia-parkinsonism (DYT3, "Lubag")

Aloysius Domingo, Ana Westenberger, Karen Gruetz, Roland Dominic Jamora, Paul Matthew Pasco, Raymond Rosales, Lillian Lee, Christine Klein (Luebeck, Germany)

Lewy Body Dementia and other dementias in movement disorders

- 188** Clinical usefulness of F18-FP-CIT PET/CT in possible dementia with Lewy bodies

Jinyoung Ahn, Hee-Tae Kim, Jae-Hyeok Heo (Seoul, Korea)

Myoclonus

- 189** Familial cortical myoclonic tremor with epilepsy in Chinese population: Clinical and neurophysiologic features in nine pedigrees from China

Zhidong Cen, Chunping Huang, Houmin Yin, Fei Xie, Xingjiao Lu, Zhiyuan Ouyang, Yuting Lou, Xia Qiu, Zhongjin Wang, Jianfeng Xiao, Meiping Ding, Wei Luo (Hangzhou, Peoples Republic of China)

- 190** Focal myoclonus-dystonia of the upper extremity secondary to a lesion of cerebellum: A case report

Guangxun Shen, Beomseok Jeon, Guangxian Nan (Changchun, Peoples Republic of China)

- 191** Fahr's Syndrome in a Filipino female with hearing loss and polycystic ovaries: A case report

Pariessa Dadgardoust (Quezon City, Philippines)

Neuroimaging

- 192** Withdrawn by author

- 193** Transcranial sonography of the substantia nigra and its correlation with iron metabolism and c-reactive protein in Parkinson's disease

Xiaodong Yang, Jiujiang Liu, Yiwei Qian, Shaoqing Xu, Qin Xiao (Shanghai, Peoples Republic of China)

- 194** Regional change in glucose metabolism of essential tremor

In-Uk Song, Kwang-Soo Lee, Yong-An Chung (Yong-In, Korea)

- 195** Cerebral perfusion SPECT for early detection of subjective memory impairment in Parkinson's disease

Kwang-Soo Lee, In-Uk Song, Jeong Wook Park (Seoul, Korea)

- 196** The prevalence and risk factors of cerebral microbleeds in patients with Parkinson's disease

Kazuo Yamashiro, Ryota Tanaka, Yasunobu Hoshino, Taku Hatano, Kenya Nishioka, Nobutaka Hattori (Tokyo, Japan)

- 197** Magnetic resonance imaging markers of Parkinson's disease: examining the combined use of DTI and ASL

Huimin Gao (Guangzhou, Peoples Republic of China)

- 198** Effect of olfactory impairment and white matter hyperintensities on cognition in Parkinson's disease

Phil Hyu Lee, Jee Hyun Ham, Young Sohn (Seoul, Korea)

- 199** Dual Time Point F-18 FP-CIT PET Imaging in

Idiopathic Parkinson's Disease

Yong-An Chung, In-Uk Song (Incheon, Korea)

- 200** Disrupted functional connectivity in Parkinson's disease patients with severe olfactory dysfunction

Hirohisa Watanabe, Epifanio Bagarinao, Noritaka Yoneyama, Kazuya Kawabata, Masahisa Katsuno, Gen Sobue, Kazuhiro Hara (Nagoya, Japan)

- 201** Clinical correlates of striatal dopamine transporter binding in Parkinson's disease

Shigeki Hirano, Hongliang Li, Shogo Furukawa, Yoshikazu Nakano, Kazuho Kojima, Ai Ishikawa, Hong Tai, Takuro Horikoshi, Takashi Uno, Satoshi Kuwabara (Chiba, Japan)

Neuropharmacology

- 202** Withdrawn by author

- 203** Withdrawn by author

- 204** The efficacy and safety of Zonisamide as adjunctive therapy in Parkinson's disease: A meta-analysis

Katrina Remigio, Gerard Raimon Saranza (Manila, Philippines)

- 205** Effect of nicotine on the pharmacokinetics of levodopa

Win Thiri Kyaw, Masahiro Nagai, Noriko Nishikawa, Hirohisa Iwaki, Masahiro Nomoto (Tohon, Japan)

- 206** Neuroprotective effect of Co enzyme Q10 against cognitive deficits associated with sleep deprivation and sleep debt: Possible role of Oxidative Stress, Mitochondrial Dysfunction and Neuroinflammatory cascades

Priyanka Chanana, Anil Kumar (Chandigarh, India)

Abstract Listing by Topic

Posters 117 – 233 will be presented on Sunday, March 13, 2016 from 11:30 – 12:30.

- 207** Efficacy and safety of Apomorphine (APO-Go[®]) Ampoules among Filipino patients insufficiently controlled by oral anti-Parkinson medications
Marc Ostrea (Quezon City, Philippines)

Neurorehabilitation in Dystonia

- 208** Efficiency criteria of correction dystonia in stages of neurorehabilitation
Dilmurod Talipov (Tashkent, Uzbekistan)

Other movement disorders

- 209** Olfactory function impairment in progressive supranuclear palsy (PSP)
Elvina Giyazitdinova, Yulduz Musayeva (Tashkent, Uzbekistan)
- 210** Incidence of early multiple system atrophy
Elvina Giyazitdinova, Yulduz Musayeva, Gulnora Rakhmibayeva (Tashkent, Uzbekistan)
- 211** Degeneration of the striatonigral dopaminergic nervous system in calcium-independent phospholipase A2 β -knockout mice
Goichi Beck, Koei Shinzawa, Hideki Mochizuki (Osaka, Japan)
- 212** Association between depression and survival in Chinese amyotrophic lateral sclerosis patients
Qianqian Wei, Bei Cao, OuRuwei Ou, HuiFang Shang (Chengdu, Peoples Republic of China)
- 213** Cognitive profile of Filipino patients with x-linked dystonia parkinsonism
Jesi Bautista, Lillian Lee, Cid Czarina Diesta, Lourdes Ledesma, Roland Dominic Jamora (Quezon City, Philippines)

Pediatric Movement disorder

- 214** Elevated plasma oligo-dimensional alpha-synuclein as a feature of lysosomal storage disorders
Elvina Giyazitdinova, Bakhtiyar Iriskulov (Tashkent, Uzbekistan)
- 215** Dystonia associated with polycythemia, liver dysfunction and hypermanganesemia due to SLC30A10 mutation, a manganese transporter gene in a Filipino adolescent with concomitant heterogenous ATP7B gene mutation
Madelyn Pascual, Jose Robles, Allan Robert Racho, Maria Luz Del Rosario, Lillian Lee (Calumpit, Philippines)
- 216** Subacute sclerosing panencephalitis presenting with truncal titubation: A case report
Ariel Rabanes, Lillian Lee (Iloilo City, Philippines)

Quality of life/caregiver burden in movement disorders

- 217** Individual Therapeutic Singing Protocol (ITSP) to improve of the vocal quality and alleviate of the depression in Parkinson's disease: Case series
Eun Young Han, Hyun Ju Chong, Kyoung-Gyu Choi, Ji Young Yun (Seoul, Korea)

Restless legs syndrome

- 218** Withdrawn by author
- 219** Impaired vascular endothelial function in patients with restless legs syndrome: A new aspect of the vascular pathophysiology
Jung Han Yoon, Min Seung Kim, Seung Yon Koh (Suwon-si, Korea)
- 220** Restless bladder in an elderly woman: an unusual variant of restless legs syndrome
Keisuke Suzuki, Masayuki Miyamoto, Tomoyuki Uchiyama, Tomoyuki Miyamoto, Koichi Hirata (Tochigi, Japan)

Spasticity

- 221** Meta-Analysis on botulinum toxin as early intervention for upper and lower limb spasticity following acute stroke and acquired severe brain injury to improve hypertonicity, disability, function and pain
Fran Efendy, Raymond Rosales, Arlene Ng (Quezon City, Philippines)
- 222** Passive ROM rehabilitation immediately following botulinum toxin injection improves outcome in post-stroke spasticity
Toshiaki Takeuchi (Tokushima City, Japan)
- 223** Hereditary spastic paraplegia in a Filipino family: A case report
Paula Ruth Siongco (Manila, Philippines)

Surgical Therapy: Other Movement Disorders

- 224** Eighty-four months outcome of the first Japanese case of X-linked dystonia-parkinsonism (XDP: DYT-3 'Lubag') improved by bilateral GPi DBS
Katsuo Kimura, Fusako Yokochi, Ryoichi Okiyama, Takashi Kawasaki, Koichi Hamada, Hirokazu Iwamuro, Makoto Taniguchi (Fujisawa, Japan)
- 225** Bilateral globus pallidus stimulation for Huntington's disease: a case report
Jie Ren, Guoming Luan (Beijing, Peoples Republic of China)



Abstract Listing by Topic

Posters 117 – 233 will be presented on Sunday, March 13, 2016 from 11:30 – 12:30.

Tremor

- 226** Essential tremor in patients with Parkinson's disease
Kateryna Kurako (Davie, FL, USA)
- 227** Withdrawn by author
- 228** Study on association between physical and genetics
role in essential tremor - A case control study
*Kovendan Kalimuthu, R. Chandirasekar, Murugan
Kadarkarai, Vincent Savariar (Coimbatore, India)*
- 229** Cardiovascular autonomic dysfunctions in essential
tremor
*Joong-Seok Kim, In-Uk Song, Jeong Wook Park (Seoul,
Korea)*
- 230** Effect of zonisamide on post-traumatic Holmes'
tremor
*Satoko Sekimoto, Genko Oyama, Nana Izawa, Sinichi
Ueno, Asuka Nakajima, Yasushi Shimo, Asuka
Nakajima, Madoka Nakajima, Atsushi Umemura,
Hajime Arai, Nobutaka Hattori (Tokyo, Japan)*

Wilson's disease, storage and metabolic movement disorders

- 231** Withdrawn by author
- 232** Side-effects of DMPS (Unithiol) infusion on the
patients with Wilson disease
*Xiao-Ping Wang, Hui Liu (Shanghai, Peoples Republic of
China)*
- 233** Wilson disease: a review and a case series
*Mishelle Imperial, Lillian Lee (Banata, San Mateo Rizd,
Philippines)*



Saturday, March 12, 2016

Poster Session: 11:30–12:30

Poster Viewing: 8:00–18:00

Location: Marriott Grand Ballroom, Ground Floor Foyer

- LBA1 Non-motor symptoms profiles between Indian patients with Parkinson's disease in West Bengal, India and White Caucasians in Europe
Anna Sauerbier, Hrishikesh Kumar, Rebecca Banerjee, Mariam Umme Kulsum, Alexandra Rizos, Lauren Perkins, Theresa Chiwera, Dhaval Trivedi, Anne Martin, Miriam Parry, K Ray Chaudhuri (London, United Kingdom)
- LBA2 Stress precedes hemifacial spasm: A retrospective study in multi-ethnic Penang, Malaysia
Kenny Tan, Gaik Bee Eow, Han Bing Chow, Chun Fai Cheah, Yuen Kang Chia, Jyh Yung Hor, Ruban Kanesalingam, Md Hanip Rafia, P.E. Samuel Easaw, Azman Ali Raymond, Thien Thien Lim (Penang, Malaysia)
- LBA3 Genomic study and subsequent in silico drug discovery for Parkinson's disease
Wataru Satake, Takeshi Uenaka, Cha Pei Chieng, Yukinori Okada, Kenichi Kashihara, Shigeo Murayama, Kazuko Hasegawa, Hideki Mochizuki, Atsushi Takeda, Mitsutoshi Yamamoto, Miho Murata, Nobutaka Hattori, Tatsushi Toda (Kobe, Japan)
- LBA4 The effect of expiratory muscle strength training in Cantonese speaking Parkinson's disease patients: A pilot study
Tiksang Eric Tong, Manwa Lawrence Ng, Yan Nan (Hong Kong)
- LBA5 Design, synthesis and anticonvulsant activity of 1, 3, 5 -triazin-2-imine/one/thione incorporated pyridazines
Ravinesh Mishra, Anees A. Siddiqui, Asif Husain, Mohd Rashid, Sweta Bhardwaj (New Delhi, India)
- LBA6 JPDA (Japan Parkinson's Disease Association)
Yoshiji Matsumoto (Japan)
- LBA7 Slower deterioration of non-motor symptoms and quality of life in LRRK2 protective variant carriers with Parkinson's disease
Xiao Deng, Bin Xiao, Hui-Hua Li, Kumar M. Prakash, Yu-Lin Ng, Yew-Long Lo, Eng-King Tan (Singapore)
- LBA8 Profile of Japanese encephalitis and autoimmune encephalitis patients in an 18-month period admitted in a tertiary hospital setting
Madelyn P. Pascual, Lillian V. Lee, Marilyn H. Ortiz (Philippines)
- LBA9 Assessment of sleep spindle density among genetically positive spinocerebellar ataxias type 1, 2 and 3 patients: A comparative study
Ragasudha Botta, Seshagiri Doniparthi, Arun Sasidharan, Ravi Yadav, Pramod Pal, Sanjeev Jain, Bindu M. Kutty (Bengaluru, India)
- LBA10 Neural underpinnings for the freezing of gait in PD: Diffusion tensor and resting state functional MRI study
Masahito Mihara, Hiroaki Fujimoto, Hironori Otomune, Yoshiyuki Watanabe, Noriaki Hattori, Hideki Mochizuki (Bengaluru, India)
- LBA11 Chronic cerebral hypoperfusion accelerates cognitive dysfunction and microvascular impairment in the PTP mouse model of Parkinson's disease
Hongmei Tang, Ruiming Zhu, Liang Gao, Kun Nie, Shujun Feng, Zhenpeng Duan, Youwen Zhang, Xin Zhao, Linmin Wang, Jiehao Zhao, Zhiheng Huang, Yuhu Zhang, Lijuan Wang (Guangzhou, China)
- LBA12 Effect of single task training and dual task training on balance in individuals with Idiopathic Parkinson's disease
Vaithiamanithi Perumal
- LBA13 Asymmetric and upper body parkinsonism in patients with idiopathic normal-pressure hydrocephalus
Jinsung Park, Pan-Woo Ko, Kyunghun Kang, Ho-Won Lee (Daegu, Korea)
- LBA14 Evaluation of TENM4 association with essential tremor in Singapore Chinese population
Yin Xia Chao, Ebonne Yu Lin Ng, Fiona Setiawan, Kandiah Nagaendran, Yuen Yih, Mei Sian Chong, Prakash Kumar, Louis Chew Seng Tan, Wing Lok Au, Yi Zhao, Zhi Dong Zhou, Murni Tio, Ratnagopal Pavanni, Eng King Tan (Singapore)
- LBA15 Rapid eye movement sleep behavior disorder symptoms correlate with domains of cognitive impairment in Parkinson's disease
Jin-Ru Zhang, Jing Chen, Zi-Jiao Yang, Hui-Jun Zhang, Yun-Ting Fu, Yun Shen, Pei-Cheng He, Cheng-jie Mao, Chun-Feng Liu (Suzhou, China)



Exhibit Area Floor Plans

Executive Rooms 7 and 9





Exhibit Area Floor Plans

Ceremonial Hall





International Parkinson and
Movement Disorder Society
Asian & Oceanian Section

Acknowledgement of Support

The International Parkinson and Movement Disorder Society – Asian and Oceanian Section (MDS-AOS) wishes to acknowledge and thank the following companies for their support:

Platinum



Medtronic

Gold

abbvie



MDS Education Information

To better fulfill its global mission of advancing the neurological sciences as they relate to the field of Movement Disorders, MDS is continually expanding its educational portfolio. This growing portfolio offers an increasing variety of high caliber continuing medical education and continuing professional development opportunities in movement disorders. For more information about the opportunities listed in this section, please visit

www.movementdisorders.org/MDS/Education.htm or
e-mail education@movementdisorders.org.

Outreach Education Programs

Developing World Education Program (DWEPE)

MDS recognizes that some countries do not have access to trained Movement Disorder Specialists and are restricted by size and/or resources from establishing a training program. Therefore, the Developing World Education Program is designed to address the needs of those countries and build rapport with local area societies that have no existing relationship with MDS.

DWEPE's are intended to support three course formats: a stand-alone course, courses joined with other local/regional meetings, and a series of courses over an extended timeframe.

Ambassador Program

This program supports the travel of one or two international experts who are MDS members to an underserved area for the purposes of education and intellectual exchange.

The MDS Ambassador Program supports members as keynote/plenary speakers at a non-MDS sponsored regional or national meeting in a disadvantaged country.

Sponsored speakers/faculty will work with the Ambassador Program host to develop material that is relevant and comprehensible to participants and meets the specified learning objectives of the meeting

Visiting Professor Program

This program supports the travel of one or two international experts who are MDS members to an underserved area for the purposes of education and intellectual exchange.

The MDS Visiting Professor Program supports members in conducting teaching seminars or giving grand-rounds in local hospitals, and/or providing input for further development in the field of movement disorders in an underserved country.

Virtual Professor Program

This program supports the virtual attendance of one or two international experts to an area of need that does not allow the physical attendance of such experts (i.e. countries on the U.S. travel warnings list or hard to travel to regions).

Sponsored speakers will develop materials relevant and comprehensible to participants and deliver these materials virtually using a webinar software.

Parkinson and Movement Disorders Curriculum

The Parkinson and Movement Disorders Curriculum provides an overview of movement disorders and a clinical approach to the evaluation and management of common movement disorders. This curriculum is specially developed for trainees, internists, general neurologists and other clinicians interested in acquiring a basic understanding of movement disorders.



Education Information

New E-Learning Portal

In alignment with the mission of MDS to advance the education of medical professionals worldwide, improve diagnosis and treatment, and encourage research in Parkinson's disease and all other movement disorders, The society now offers a full spectrum of e-learning educational opportunities to members and non-members alike.

These MDS e-learning courses will now be presented using a new custom Learning Management System (LMS) software. This new system creates a single portal that houses all MDS educational activities, and allows all users to review their progress, retrieve certificates and keep track of their e-learning CME credits. Questions regarding the new e-learning portal and virtual educational opportunities, can be sent via e-mail to e-learning@movementdisorders.org.

Online CME Activities

All of the following CME activities are offered through the MDS e-learning portal:

Journal CME

These modules offer CME credit for the review of *Movement Disorders Journal* articles. MDS is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide certified continuing medical education for physicians. MDS designates these educational activities for a maximum of 1.0 *AMA PRA Category 1 Credit™* each. Upon successful completion of a Journal CME activity, users will receive a CME certificate documenting their achievement.

Coffee Break CME

This program was designed to provide continuing education critical to providing the best care possible. Scientific content is presented in a modular format, where each module is focused on a single topic which can be completed in a short period of time, providing the clinician with updated information relevant to their practice. Both standard approaches and new advances are highlighted.

The scope of this program includes modules on: parkinsonism, tremor, dystonia, chorea, and other topics as identified. After users have registered for a module, they are able to log in to the site as many times as needed to view all the material. At the beginning and completion of each module, participants are asked content-related questions to gauge their learning.

MDS is accredited by the ACCME to certify 2.0 *AMA PRA Category 1 Credit™* for each module. Upon successful completion of a Coffee Break CME activity, users will receive a CME certificate documenting their achievement.

Device Aided Medical Therapies

Device-Aided Medical Therapies in Parkinson's Disease is an online course series designed by a panel of worldwide specialists around the main practical issues involved with device-aided treatments of Parkinson's disease. Each module takes approximately one hour to complete.

This course series, provided as ten separate modules, addresses issues such as identifying patients who may or may not benefit from the treatment, recognizing the titration and the monitoring of clinical response, recognizing the main complications and managing them, and comparing these treatments with conventional oral dopaminergic therapies, as well as against each other.

MDS designates these educational activities for a maximum of 1.0 *AMA PRA Category 1 Credit™* each. Upon successful completion of a Device-Aided Medical Therapy activity, users will receive a CME certificate documenting their achievement.

Other Online Education Resources

MDS provides a variety of online educational activities in addition to streaming video and CME programming. The following educational tools are available on the MDS website.

Fundamentals of Movement Disorders

The goal of this new video series is to provide residents an overview of movement disorders with a clinical approach to the evaluation and management of common disorders. The 31 presentations, delivered by expert physicians from around the world, cover the fundamental topics in movement disorders to help provide a base knowledge for residents. All Fundamentals of Movement Disorders presentations are offered through the MDS e-learning portal.

MDS Video Library

This members only library consists of video supplements from the *Movement Disorders Journal* since 1986. Videos can be searched by keyword, author, volume and issue or a combination of these fields.

2016 MDS Education Calendar



International Parkinson and
Movement Disorder Society




Pathogenesis and Management of Pain in Parkinson's Disease

April 18-19, 2016
Padua, Italy




MDS-PAS Movement Disorders School for Neurology Residents

April 30-May 1, 2016
Atlanta, GA, USA



Allied Health Team Training for Parkinson's Disease

May 12-14, 2016
Columbus, OH, USA



Middle East Continuing Education for Parkinson's Disease and Movement Disorders

May 19, 2016
Amman, Jordan



Rehabilitation Updates in Parkinson's Disease

May 20, 2016
Amman, Jordan



Parkinson's Disease and Other Movement Disorders: A Practical Approach

May 21, 2016
Houston, TX, USA



Deep Brain Stimulation for Movement Disorders

July 15-16, 2016
Seoul, Korea



A Comprehensive Review of Movement Disorders for the Clinical Practitioner

July 31-August 1, 2016
Aspen, CO, USA



Basic Scientists Summer School

August 4-6, 2016
Suzhou, China



Physiotherapy Summer School

September 8-10, 2016
Leuven, Belgium



Deep Brain Stimulation for Movement Disorders - Advanced Course

October 13-14, 2016
Würzburg, Germany



Myoclonus and Other Jerky Movements

October 13-14, 2016
Groningen, Netherlands

Dates and locations are subject to change. For a complete up-to-date list of courses, visit
www.movementdisorders.org/MDS/education.htm



International Parkinson and
Movement Disorder Society

20th International Congress of Parkinson's Disease and Movement Disorders

JUNE 19-23, 2016 • BERLIN, GERMANY

Come Join Us
www.mdscongress2016.org



IMPORTANT DATES

April 15, 2016 Early Registration Deadline

May 18, 2016 Final Pre-Registration Deadline

A Novartis-sponsored Symposium:
5th Asian and Oceanian Parkinson's Disease and Movement Disorders Congress

A person with white hair, seen from behind, stands in a doorway looking out at a bright, sunny landscape with a blue sky and green grass. The scene is framed by the open white doors of the doorway.

Challenges, Trends and Future Perspectives in Parkinson's Disease and Dementia

Friday 11th, March 2016 • 13:15 – 14:15 • Marriott Grand Ballroom Hotel • Manila Philippines

A corporate satellite symposium supported by AbbVie at the
5th Asian and Oceanian Parkinson's Disease and Movement Disorders Congress
11–13 March, 2016 • Manila, Philippines

ABBVIE INVITES YOU TO JOIN A SYMPOSIUM AT THE AOPMC-MDS

**Friday, 11 March 2016 • 4:00pm–5:00pm
Grand Ballroom, Marriott Hotel
Manila, Philippines**

At this educational symposium, the expert panel will discuss the advanced Parkinson's Disease landscape; from natural progression to latest evidence for therapeutic options, including patient profile considerations in the clinical setting.

Advanced Parkinson's Disease – Natural Progression, Emerging Data and Patient Profile Considerations in the Clinical Setting

Introduction

Prof Carolyn Sue – Royal North Shore Hospital, Australia

Advanced PD Landscape – Incidence, definition & patient considerations including emerging data for advanced PD treatment options

Assoc Prof Tom Kimber – Royal Adelaide Hospital, Australia

Which patient for which therapy and when? Is there a clear patient profile for the different advanced PD therapies?

Dr Andrew Evans – Royal Melbourne Hospital, Australia

Discussion and audience questions

How can we empower our Parkinson's disease patients and optimise clinical outcomes?

Friday 11th March 2016 | 17:15–18:15

Chairperson – Dr. Andrew Evans (Royal Melbourne Hospital, Melbourne, Australia)

Patients & neurologists – a partnership for success

Dr. Andrew Evans

Royal Melbourne Hospital, Melbourne, Australia

Integrating patient concerns into disease management

Prof. Lim Shen-Yang

Department of Medicine, University of Malaya,
Kuala Lumpur, Malaysia

Joint decisions on treating nocturnal symptoms – what do patients need to know?

Prof. Roongroj Bhidayasiri

Chulalongkorn Centre of Excellence for Parkinson's
Disease and Related Disorders, Chulalongkorn
University Hospital, Bangkok, Thailand



Christer, living with Parkinson's disease



Inspired by **patients.**
Driven by **science.**



Abbott
A Promise for Life

© UCB Biopharma SPRL 2016. All rights reserved.
This symposium is sponsored by UCB
SEA-0020-012015



APO-go[®]
Apomorphine

Regain control of
Parkinson's disease symptoms
with APO-go

STADA
ASIA

Pharmaceutical Company of the German Pharmacists



MSD K.K. www.msd.co.jp



大阪城 (Osaka Castle)

For Patients with Parkinson's Disease

Fujimoto 藤本製薬グループ
エフピー株式会社

FP Pharmaceutical Corp. is
pleased to be a supporter of
the 5th Asian and Oceanian
Parkinson's Disease and Movement
Disorders Congress


Manila, Philippines
March 11 - 13, 2016

We dedicate ourselves to
distribution of Selegiline in Japan.

Fujimoto Fujimoto Pharmaceutical Group

FP Pharmaceutical Corp.

1-3-40 Nishiotsuka, Matsubara, Osaka,
580-0011 JAPAN



International Parkinson and
Movement Disorder Society

Certifies that

has attended the 5th Asian and Oceanian Parkinson's Disease
and Movement Disorders Congress on March 11-13, 2016 at the Marriott Grand
Ballroom located in Manila, Philippines.

Oscar Gershanik
President,
International Parkinson and
Movement Disorder Society,
2015-2017

Nobutaka Hattori
Chair,
5th AOPMC Oversight Committee

Raymond Rosales
Chair,
5th AOPMC Scientific Program Committee

Asian perspectives on recognition and treatment of levodopa-induced motor complications in Parkinson's disease

Chaired by Roland Dominic Jamora, Philippines

Date: Saturday 12th March 2016

Time: 13:00–14:00

Venue: Grand Ballroom, Rooms 1+2, 2nd Floor

Programme

Chairman's introduction

Roland Dominic Jamora,
Philippines

Clinical management of Parkinson's disease in Asia
– recent developments in the use of levodopa

Piu Chan,
China

Levodopa-related motor complications in PD
– mechanisms and treatment approaches

Werner Poewe,
Austria

Panel discussion

Led by Chairman

Satellite symposium at the 5th Asian and Oceanian Parkinson's Disease and Movement Disorders Congress


11th–13th March 2016

Marriott Hotel Manila, Manila, Philippines

MEDTRONIC ANNOUNCES **THE WORLD'S FIRST AND ONLY FULL-BODY MR CONDITIONAL DBS SYSTEMS***



Damian, Implanted with
Medtronic Activa® PC



FDA APPROVED **CE**

* Medtronic DBS systems are MR Conditional, indicating they are safe in the MR environment as long as certain conditions are met. Read and fully understand the MRI Guidelines for Medtronic deep brain stimulation systems before conducting the MRI examination. Go to www.medtronic.com/mri or contact Medtronic at 1-800-707-0933 for a copy. Also review current MRI manufacturer labeling before conducting the MRI.

Important safety information is available at the Medtronic exhibit booth.

www.medtronic.com

ASEAN Headquarter
49 Changi South
Avenue 2 Singapore
486056 Singapore
Tel: +65 6436 5000
Fax: +65 6776 6355

Medtronic Philippines, Inc.
Unit 810, 8th Floor Sun Life
Centre, 5th Avenue Corner
Rizal Drive, Bonifacio
Global City Fort Bonifacio
Taguig City, 1634
Philippines
Tel: +632 224 1864

Medtronic